U.S. patent application number 16/502457 was filed with the patent office on 2019-10-24 for peptide-mediated non-covalent delivery of active agents across the blood-brain barrier.
The applicant listed for this patent is Mayo Foundation for Medical Education and Research. Invention is credited to Geoffry L. Curran, Robert B. Jenkins, Val J. Lowe, Eric W. Mahlum, Joseph F. Poduslo, Gobinda Sarkar.
Application Number | 20190322723 16/502457 |
Document ID | / |
Family ID | 43450155 |
Filed Date | 2019-10-24 |
![](/patent/app/20190322723/US20190322723A1-20191024-C00001.png)
![](/patent/app/20190322723/US20190322723A1-20191024-D00001.png)
![](/patent/app/20190322723/US20190322723A1-20191024-D00002.png)
![](/patent/app/20190322723/US20190322723A1-20191024-D00003.png)
![](/patent/app/20190322723/US20190322723A1-20191024-D00004.png)
![](/patent/app/20190322723/US20190322723A1-20191024-D00005.png)
![](/patent/app/20190322723/US20190322723A1-20191024-D00006.png)
![](/patent/app/20190322723/US20190322723A1-20191024-D00007.png)
![](/patent/app/20190322723/US20190322723A1-20191024-D00008.png)
![](/patent/app/20190322723/US20190322723A1-20191024-D00009.png)
United States Patent
Application |
20190322723 |
Kind Code |
A1 |
Curran; Geoffry L. ; et
al. |
October 24, 2019 |
Peptide-Mediated Non-Covalent Delivery of Active Agents Across the
Blood-Brain Barrier
Abstract
The peptides described herein can function as carrier peptides.
These peptides can associate with (e.g., non-covalently bind)
biologically active molecules or imaging agents to transport the
biologically active molecules or imaging across the blood-brain
barrier. In some cases, such transport may increase the
effectiveness of the biological molecules or imaging agents.
Inventors: |
Curran; Geoffry L.;
(Rochester, MN) ; Sarkar; Gobinda; (Rochester,
MN) ; Poduslo; Joseph F.; (Zumbro Falls, MN) ;
Jenkins; Robert B.; (Rochester, MN) ; Lowe; Val
J.; (Rochester, MN) ; Mahlum; Eric W.;
(Rochester, MN) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Mayo Foundation for Medical Education and Research |
Rochester |
MN |
US |
|
|
Family ID: |
43450155 |
Appl. No.: |
16/502457 |
Filed: |
July 3, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15422827 |
Feb 2, 2017 |
10377813 |
|
|
16502457 |
|
|
|
|
14281389 |
May 19, 2014 |
9597408 |
|
|
15422827 |
|
|
|
|
13383710 |
Jan 12, 2012 |
|
|
|
PCT/US2010/041924 |
Jul 14, 2010 |
|
|
|
14281389 |
|
|
|
|
61225412 |
Jul 14, 2009 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 31/18 20180101;
A61P 25/00 20180101; A61K 49/0056 20130101; A61K 39/39533 20130101;
A61P 25/08 20180101; A61P 25/28 20180101; A61K 51/088 20130101;
A61P 25/16 20180101; C07K 14/775 20130101; A61K 49/0058 20130101;
A61K 38/47 20130101; Y02A 50/393 20180101; A61K 51/1018 20130101;
A61K 51/12 20130101; Y02A 50/30 20180101; A61P 35/00 20180101; C12Y
302/01023 20130101; A61K 47/64 20170801 |
International
Class: |
C07K 14/775 20060101
C07K014/775; A61K 39/395 20060101 A61K039/395; A61K 47/64 20060101
A61K047/64; A61K 51/10 20060101 A61K051/10; A61K 51/08 20060101
A61K051/08; A61K 51/12 20060101 A61K051/12; A61K 49/00 20060101
A61K049/00; A61K 38/47 20060101 A61K038/47 |
Claims
1. (canceled)
2. A method of transporting a nerve growth factor across the
blood-brain barrier of a subject, the method comprising
administering to the subject a complex, or a pharmaceutically
acceptable salt thereof, comprising the biologically active
molecule or imaging agent associated with a carrier peptide;
wherein the carrier peptide comprises the sequence:
X.sub.n--[B].sub.m or a pharmaceutically acceptable salt thereof,
wherein: X is a hydrophilic amino acid; B is a blood-brain barrier
agent; n is an integer from 4 to 50; and m is integer from 1 to
3.
3. The method of claim 2, wherein each X is independently chosen
from arginine, asparagine, aspartic acid, glutamic acid, glutamine,
lysine, serine, threonine, and tyrosine.
4. The method of claim 3, wherein n is chosen from 4, 8, 12, 16,
and 20.
5. The method of claim 4, wherein n is 16.
6. The method of claim 2, wherein m is 1.
7. The method of claim 2, wherein the nerve growth factor is
non-covalently bound to the carrier peptide.
8. The method of claim 2, wherein the blood-brain barrier agent
comprises a receptor binding domain of an apolipoprotein is chosen
from the receptor binding domain of ApoA, ApoB, ApoC, ApoD, ApoE,
ApoE2, ApoE3, and ApoE4.
9. The method of claim 2, wherein B comprises the sequence:
TABLE-US-00011 (SEQ ID NO: 29)
L-R-X1-R-X2-X3-X4-H-L-R-X5-X6-X7-K-R-L-X8-R-D-X9
wherein: X1 is selected from the group consisting of A, L, S, and
V; X2 is selected from the group consisting of L and M; X3 is
selected from the group consisting of A and S; X4 is selected from
the group consisting of N, S, and T; X5 is selected from the group
consisting of K and N; X6 is selected from the group consisting of
L, M, and V; X7 is selected from the group consisting of R and P;
X8 is selected from the group consisting of L and M; and X9 is
selected from the group consisting of A and L.
10. The method of claim 9, wherein the carrier peptide comprises
the sequence: TABLE-US-00012 (SEQ ID NO: 143)
[X].sub.n-L-R-X1-R-X2-X3-X4-H-L-R-X5-X6-X7-K-R-L-X8-R- D-X9
wherein: X is lysine.
11. The method of claim 10, wherein the carrier peptide comprises
the sequence: TABLE-US-00013 (SEQ ID NO: 19)
K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 20)
K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L- R-D-A; (SEQ ID
NO: 21) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-
K-R-L-L-R-D-A; (SEQ ID NO: 22)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-
R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 23)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
A-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 46)
K-K-K-K-L-R-S-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 47)
K-K-K-K-K-K-K-K-L-R-S-R-L-A-S-H-L-R-K-L-R-K-R-L-L- R-D-A; (SEQ ID
NO: 48) K-K-K-K-K-K-K-K-K-K-K-K-L-R-S-R-L-A-S-H-L-R-K-L-R-
K-R-L-L-R-D-A; (SEQ ID NO: 49)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-S-R-L-A-S-H-L-
R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 50)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-S-R-L-
A-S-H-L-R-K-L-R-K-R-L-L-R-D-A ; (SEQ ID NO: 51)
K-K-K-K-L-R-V-R-M-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 52)
K-K-K-K-K-K-K-K-L-R-V-R-M-A-S-H-L-R-K-L-R-K-R-L-L- R-D-A; (SEQ ID
NO: 53) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-M-A-S-H-L-R-K-L-R-
K-R-L-L-R-D-A; (SEQ ID NO: 54)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-M-A-S-H-L-
R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 55)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-M-
A-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 56)
K-K-K-K-L-R-V-R-L-A-T-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 57)
K-K-K-K-K-K-K-K-L-R-V-R-L-A-T-H-L-R-K-L-R-K-R-L-L- R-D-A; (SEQ ID
NO: 58) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-T-H-L-R-K-L-R-
K-R-L-L-R-D-A; (SEQ ID NO: 59)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-T-H-L-
R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 60)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
A-T-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 61)
K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-P-K-R-L-L-R-D-A; (SEQ ID NO: 62)
K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-P-K-R-L-L- R-D-A; (SEQ ID
NO: 63) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-P-
K-R-L-L-R-D-A; (SEQ ID NO: 64)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-
R-K-L-P-K-R-L-L-R-D-A; (SEQ ID NO: 65)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
A-S-H-L-R-K-L-P-K-R-L-L-R-D-A; (SEQ ID NO: 66)
K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-M-R-D-A; (SEQ ID NO: 67)
K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-M- R-D-A; (SEQ ID
NO: 68) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-
K-R-L-M-R-D-A; (SEQ ID NO: 69)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-
R-K-L-R-K-R-L-M-R-D-A; (SEQ ID NO: 70)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
A-S-H-L-R-K-L-R-K-R-L-M-R-D-A; (SEQ ID NO: 71)
K-K-K-K-L-R-V-R-L-A-S-H-L-R-N-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 72)
K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-N-L-R-K-R-L-L- R-D-A; (SEQ ID
NO: 73) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-N-L-R-
K-R-L-L-R-D-A; (SEQ ID NO: 74)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-
R-N-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 75)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
A-S-H-L-R-N-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 76)
K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-V-R-K-R-L-L-R-D-A; (SEQ ID NO: 77)
K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-V-R-K-R-L-L- R-D-A; (SEQ ID
NO: 78) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-V-R-
K-R-L-L-R-D-A; (SEQ ID NO: 79)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-
R-K-V-R-K-R-L-L-R-D-A; (SEQ ID NO: 80)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
A-S-H-L-R-K-V-R-K-R-L-L-R-D-A; (SEQ ID NO: 81)
K-K-K-K-L-R-V-R-M-S-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 82)
K-K-K-K-K-K-K-K-L-R-V-R-M-S-S-H-L-R-K-L-R-K-R-L-L- R-D-A; (SEQ ID
NO: 83) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-M-S-S-H-L-R-K-L-R-
K-R-L-L-R-D-A; (SEQ ID NO: 84)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-M-S-S-H-L-
R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 85)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-M-
S-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 86)
K-K-K-K-L-R-V-R-L-A-S-H-L-R-N-V-R-K-R-L-L-R-D-A; (SEQ ID NO: 87)
K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-N-V-R-K-R-L-L- R-D-A; (SEQ ID
NO: 88) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-N-V-R-
K-R-L-L-R-D-A; (SEQ ID NO: 89)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-
R-N-V-R-K-R-L-L-R-D-A; (SEQ ID NO: 90)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
A-S-H-L-R-N-V-R-K-R-L-L-R-D-A; (SEQ ID NO: 91)
K-K-K-K-L-R-V-R-L-A-S-H-L-R-N-M-R-K-R-L-L-R-D-A; (SEQ ID NO: 92)
K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-N-M-R-K-R-L-L- R-D-A; (SEQ ID
NO: 93) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-N-M-R-
K-R-L-L-R-D-A; (SEQ ID NO: 94)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-
R-N-M-R-K-R-L-L-R-D-A; (SEQ ID NO: 95)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
A-S-H-L-R-N-M-R-K-R-L-L-R-D-A; (SEQ ID NO: 96)
K-K-K-K-L-R-A-R-M-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 97)
K-K-K-K-K-K-K-K-L-R-A-R-M-A-S-H-L-R-K-L-R-K-R-L-L- R-D-A; (SEQ ID
NO: 98) K-K-K-K-K-K-K-K-K-K-K-K-L-R-A-R-M-A-S-H-L-R-K-L-R-
K-R-L-L-R-D-A; (SEQ ID NO: 99)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-A-R-M-A-S-H-L-
R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 100)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-A-R-M-
A-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 101)
K-K-K-K-L-R-V-R-L-S-S-H-L-R-K-L-R-K-R-L-M-R-D-A; (SEQ ID NO: 102)
K-K-K-K-K-K-K-K-L-R-V-R-L-S-S-H-L-R-K-L-R-K-R-L-M- R-D-A; (SEQ ID
NO: 103) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-S-S-H-L-R-K-L-R-
K-R-L-M-R-D-A; (SEQ ID NO: 104)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-S-S-H-L-
R-K-L-R-K-R-L-M-R-D-A; (SEQ ID NO: 105)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
S-S-H-L-R-K-L-R-K-R-L-M-R-D-A; (SEQ ID NO: 106)
K-K-K-K-L-R-S-R-L-A-S-H-L-R-K-L-R-K-R-L-M-R-D-A;
(SEQ ID NO: 107) K-K-K-K-K-K-K-K-L-R-S-R-L-A-S-H-L-R-K-L-R-K-R-L-M-
R-D-A; (SEQ ID NO: 108)
K-K-K-K-K-K-K-K-K-K-K-K-L-R-S-R-L-A-S-H-L-R-K-L-R- K-R-L-M-R-D-A;
(SEQ ID NO: 109) K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-S-R-L-A-S-H-L-
R-K-L-R-K-R-L-M-R-D-A; (SEQ ID NO: 110)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-S-R-L-
A-S-H-L-R-K-L-R-K-R-L-M-R-D-A; (SEQ ID NO: 111)
K-K-K-K-L-R-V-R-L-S-S-H-L-P-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 112)
K-K-K-K-K-K-K-K-L-R-V-R-L-S-S-H-L-P-K-L-R-K-R-L-L- R-D-A; (SEQ ID
NO: 113) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-S-S-H-L-P-K-L-R-
K-R-L-L-R-D-A; (SEQ ID NO: 114)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-S-S-H-L-
P-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 115)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
S-S-H-L-P-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 116)
K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-M-R-K-R-L-M-R-D-A; (SEQ ID NO: 117)
K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-M-R-K-R-L-M- R-D-A; (SEQ ID
NO: 118) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-M-R-
K-R-L-M-R-D-A; (SEQ ID NO: 119)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-
R-K-M-R-K-R-L-M-R-D-A; (SEQ ID NO: 120)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
A-S-H-L-R-K-M-R-K-R-L-M-R-D-A; (SEQ ID NO: 121)
K-K-K-K-L-R-V-R-L-A-S-H-L-R-N-L-P-K-R-L-L-R-D-A; (SEQ ID NO: 122)
K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-N-L-P-K-R-L-L- R-D-A; (SEQ ID
NO: 123) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-N-L-P-
K-R-L-L-R-D-A; (SEQ ID NO: 124)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-
R-N-L-P-K-R-L-L-R-D-A; (SEQ ID NO: 125)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
A-S-H-L-R-N-L-P-K-R-L-L-R-D-A; (SEQ ID NO: 131)
K-K-K-K-L-R-L-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-L; (SEQ ID NO: 132)
K-K-K-K-K-K-K-K-L-R-L-R-L-A-S-H-L-R-K-L-R-K-R-L-L- R-D-L; (SEQ ID
NO: 133) K-K-K-K-K-K-K-K-K-K-K-K-L-R-L-R-L-A-S-H-L-R-K-L-R-
K-R-L-L-R-D-L; (SEQ ID NO: 134)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-L-R-L-A-S-H-L-
R-K-L-R-K-R-L-L-R-D-L; (SEQ ID NO: 135)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-L-R-L-
A-S-H-L-R-K-L-R-K-R-L-L-R-D-L; (SEQ ID NO: 136)
K-K-K-K-L-R-V-R-L-A-N-H-L-R-K-L-R-K-R-L-L-R-D-L; (SEQ ID NO: 137)
K-K-K-K-K-K-K-K-L-R-V-R-L-A-N-H-L-R-K-L-R-K-R-L-L- R-D-L; (SEQ ID
NO: 138) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-N-H-L-R-K-L-R-
K-R-L-L-R-D-L; (SEQ ID NO: 139)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-N-H-L-
R-K-L-R-K-R-L-L-R-D-L; or (SEQ ID NO: 140)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
A-N-H-L-R-K-L-R-K-R-L-L-R-D-L.
12. A method of treating a brain disorder in a subject, the method
comprising administering to the subject a complex, or a
pharmaceutically acceptable salt thereof, comprising a nerve growth
factor associated with a carrier peptide, wherein the carrier
peptide comprises the sequence: X.sub.n--[B].sub.m wherein: X is a
hydrophilic amino acid; B is a blood-brain barrier agent; n is an
integer from 4 to 50; and m is integer from 1 to 3.
13. The method of claim 12, wherein the brain disorder is chosen
from: meningitis, epilepsy, multiple sclerosis, neuromyelitis
optica, late-stage neurological trypanosomiasis, Parkinson's,
progressive multifocal leukoencephalopathy, De Vivo disease,
Alzheimer's disease, HIV Encephalitis, and cancer.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 15/422,827, filed Feb. 2, 2017, which is a continuation of U.S.
application Ser. No. 14/281,389, filed May 19, 2014 (now U.S. Pat.
No. 9,597,408), which is a divisional of U.S. application Ser. No.
13/383,710, filed Jan. 12, 2012 (Abandoned), which is a National
Stage application under 35 U.S.C. .sctn. 371 of International
Application No. PCT/US2010/041924, filed Jul. 14, 2010, which
claims priority to U.S. Provisional Application Ser. No.
61/225,412, filed on Jul. 14, 2009, which are incorporated by
reference in their entirety herein.
TECHNICAL FIELD
[0002] This disclosure relates to carrier peptides, including
compositions and methods of using the same. In particular, the
disclosure relates to carrier peptides capable of delivering active
agents across the blood-brain barrier and compositions and methods
of using the same.
BACKGROUND
[0003] The blood-brain barrier (BBB) prevents most macromolecules
(e.g., DNA, RNA, and polypeptides) and many small molecules from
entering the brain. The BBB is principally composed of specialized
endothelial cells with highly restrictive tight junctions,
consequently, passage of substances, small and large, from the
blood into the central nervous system is controlled by the BBB.
This structure makes treatment and management of patients with
neurological diseases and disorders (e.g., brain cancer and
Alzheimer's disease) difficult as many therapeutic agents cannot be
delivered across the BBB with desirable efficiency.
SUMMARY
[0004] The peptides described herein can function as carrier
peptides. These peptides can associate with (e.g., non-covalently
bind) biologically active molecules and imaging agents to transport
the biologically active molecules and imaging agents across the
blood-brain barrier. In some cases, such transport may increase the
effectiveness of the biological molecules and imaging agents.
[0005] A carrier peptide, as described herein, can include the
sequence:
X.sub.n--[B].sub.m
or a pharmaceutically acceptable salt thereof, wherein: X is a
hydrophilic amino acid; B is a blood-brain barrier agent; n is an
integer from 4 to 50; and m is integer from 1 to 3.
[0006] In some embodiments, the blood-brain barrier agent is not
L-R-K-L-R-K-R-L-L-R-L-R-K-L-R-K-R-L-L-R (SEQ ID NO:141).
[0007] A hydrophilic amino acid (X) can be chosen from arginine,
asparagine, aspartic acid, glutamic acid, glutamine, histidine,
lysine, serine, threonine, tyrosine, or a combination thereof. For
example, in some embodiments, X.sub.n can comprise ten lysines and
six arginines; six lysines and sixteen arginines; eight lysines,
eight arginines, and eight histidines. In some embodiments, X is
lysine.
[0008] The variable n is an integer ranging from 4 to 50 (e.g., 4,
6, 8, 10, 12, 16, 20, 24, 26, 28, 32, 36, 40, 42, 44, 48, and 50).
In some embodiments, n is chosen from 4, 8, 12, 16, and 20. In some
embodiments, n is 16. In some embodiments, m is 1.
[0009] The blood-brain barrier agent can be a receptor binding
domain of an apolipoprotein. For example, the receptor binding
domain of an apolipoprotein can be chosen from the receptor binding
domain of ApoA, ApoB, ApoC, ApoD, ApoE, ApoE2, ApoE3, and ApoE4. In
some embodiments, the receptor binding domain of an apolipoprotein
is chosen from the receptor binding domain of ApoB and ApoE.
[0010] The blood-brain barrier agent can also include a polypeptide
sequence having at least 80% sequence identity to:
TABLE-US-00001 (SEQ ID NO: 13)
L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 14)
S-S-V-I-D-A-L-Q-Y-K-L-E-G-T-T-R-L-T-R-K-R-G-L-K-L-
A-T-A-L-S-L-S-N-K-F-V-E-G-S-H; (SEQ ID NO: 15)
Y-P-A-K-P-E-A-P-G-E-D-A-S-P-E-E-L-S-R-Y-Y-A-S-L-R-
H-Y-L-N-L-V-T-R-Q-R-Y*; (SEQ ID NO: 16)
A-K-P-E-A-P-G-E-D-A-S-P-E-E-L-S-R-Y-Y-A-S-L-R-H-Y-
L-N-L-V-T-R-Q-R-Y*; (SEQ ID NO: 17)
Y-P-S-D-P-D-N-P-G-E-D-A-P-A-E-D-L-A-R-Y-Y-S-A-L-R-
H-Y-I-N-L-I-T-R-Q-R-Y*; or (SEQ ID NO: 18)
A-P-L-E-P-V-Y-P-G-D-D-A-T-P-E-Q-M-A-Q-Y-A-A-E-L-R-
R-Y-I-N-M-L-T-R-P-R-Y*,
wherein Y* is tyrosine or a tyrosine derivative. In some
embodiments, the polypeptide is less than 100 amino acids in
length.
[0011] Examples of a carrier peptide can include:
TABLE-US-00002 (SEQ ID NO: 19)
K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 20)
K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L- R-D-A; (SEQ ID
NO: 21) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-
K-R-L-L-R-D-A; (SEQ ID NO: 22)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-
R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 23)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
A-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 24)
K-K-K-K-S-S-V-I-D-A-L-Q-Y-K-L-E-G-T-T-R-L-T-R-K-R-
G-L-K-L-A-T-A-L-S-L-S-N-K-F-V-E-G-S-H; (SEQ ID NO: 25)
K-K-K-K-K-K-K-K-S-S-V-I-D-A-L-Q-Y-K-L-E-G-T-T-R-L-
T-R-K-R-G-L-K-L-A-T-A-L-S-L-S-N-K-F-V-E-G-S-H; (SEQ ID NO: 26)
K-K-K-K-K-K-K-K-K-K-K-K-S-S-V-I-D-A-L-Q-Y-K-L-E-G-
T-T-R-L-T-R-K-R-G-L-K-L-A-T-A-L-S-L-S-N-K-F-V-E-G- S-H; (SEQ ID NO:
27) K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-S-S-V-I-D-A-L-Q-Y-
K-L-E-G-T-T-R-L-T-R-K-R-G-L-K-L-A-T-A-L-S-L-S-N-K- F-V-E-G-S-H; and
(SEQ ID NO: 28) K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-S-S-V-I-D-
A-L-Q-Y-K-L-E-G-T-T-R-L-T-R-K-R-G-L-K-L-A-T-A-L-S-
L-S-N-K-F-V-E-G-S-H.
[0012] Further provided herein is a complex, or a pharmaceutically
acceptable salt thereof, having a biologically active molecule or
an imaging agent associated with a carrier peptide, as described
above. In some embodiments, the biologically active molecule or
imaging agent is non-covalently bound to the carrier peptide.
[0013] An imaging agent can be any chemical or substance which is
used to provide the signal or contrast in imaging. For example, the
imaging agent can be .sup.125I-IgG or magnevist. A biologically
active molecule can include a polypeptide; oligonucleotide;
plasmid; small molecule; antibody; antibody fragment; carbohydrate;
polysaccharide; lipid; glycolipid; antigen; and antigenic peptide.
In some embodiments, the biologically active molecule is chosen
from a: polypeptide; oligonucleotide; and plasmid. An
oligonucleotide can include a coding DNA sequence; antisense DNA
sequence; mRNA, antisense RNA sequence; RNAi; and siRNA. In some
embodiments, the biologically active molecule is a small molecule,
for example, a therapeutic agent.
[0014] The carrier peptides and complexes of carrier peptides and
biologically active agents or imaging agents have various uses and
can be used in various methods. For example, provided herein is a
method of transporting a biologically active molecule or imaging
agent across the blood-brain barrier of a subject. The method can
include administering to the subject a complex, or a
pharmaceutically acceptable salt thereof, having the biologically
active molecule or imaging agent associated with a carrier
peptide.
[0015] Also provided is a method of treating a brain disorder in a
subject. The method can include administering to the subject a
complex, or a pharmaceutically acceptable salt thereof, having a
biologically active agent associated with a carrier peptide. The
brain disorder can be chosen from meningitis, epilepsy, multiple
sclerosis, neuromyelitis optica, late-stage neurological
trypanosomiasis, Parkinson's, progressive multifocal
leukoencephalopathy, De Vivo disease, Alzheimer's disease, HIV
Encephalitis, and cancer.
[0016] This disclosure further provides a method of imaging the
central nervous system of a subject. The method can include
administering to the subject a complex, or a pharmaceutically
acceptable salt thereof, comprising an imaging agent associated
with a carrier peptide; and imaging the central nervous system of
the subject.
[0017] Pharmaceutical compositions are also disclosed. A
pharmaceutical composition can include a complex, or a
pharmaceutically acceptable salt thereof, having a biologically
active molecule or imaging agent, a carrier peptide, and a
pharmaceutically acceptable carrier.
[0018] Finally, kits are also provided. A kit can include a carrier
peptide. In some embodiments, the kit further includes a
biologically active molecule or an imaging agent.
[0019] The details of one or more embodiments of the invention are
set forth in the accompanying drawings and the description below.
Other features, objects, and advantages of the invention will be
apparent from the description and drawings, and from the
claims.
DESCRIPTION OF DRAWINGS
[0020] FIG. 1 is a series of images illustrating the differences
between delivery of Alexa-IgG complexed to K.sub.16ApoE (SEQ ID NO:
22) into brain and uncomplexed Alexa-IgG.
[0021] FIG. 2 illustrates the accumulation of radioactive IgG 4.1
in mouse brain aided by K.sub.16ApoE (SEQ ID NO: 22).
[0022] FIG. 3 shows delivery of K16APoE-mediated (SEQ ID NO: 22)
beta-galactosidase in brain (Top) and in other organs (Bottom). In
one experiment, beta-galactosidase was injected in mice mixed with
(FIG. 3A') and without K16ApoE (SEQ ID NO: 22) (FIG. 3A), brain
slices made six hours after injection were stained for enzyme
activity (top). In a separate related experiment, slides were made
from different organs and stained for beta-galactosidase activity
after delivery without (FIG. 3B-G) and with K16ApoE (SEQ ID NO: 22)
(FIG. 3B'-G'), B--brain; C--heart, D--kidney, E--lung, F--liver,
G--spleen.
[0023] FIG. 4 shows the evaluation of K16ApoE-mediated delivery of
IgG (A) and IgM (B) in mice brains by microSPECT. Imaging was done
at 1 hour intervals up to six hours, after which cardiac perfusion
was performed, and final imaging carried out 30 minutes after
perfusion. Left bars--with K16ApoE (SEQ ID NO: 22); Right bars--no
K16ApoE (SEQ ID NO: 22).
[0024] FIG. 5 illustrates labeling of amyloid plaques with a
plaque-specific antibody delivered via K16ApoE (SEQ ID NO: 22) in
brains of mice models of Alzheimer's disease. Two mice with
Alzheimer's disease were used: one represented by A, C and E, while
the other is represented by B, D and F. A, C and E represent
adjacent brain sections from one mouse, whereas B, D and F
represent adjacent brain sections from another mouse. A,
B--thioflavine S staining; C, D--immunostaining to identify plaques
using the 4G8 as the primary antibody, and an anti-mouse antibody
as the secondary antibody; E, F--immunostaining using the secondary
antibody only. The 4G8 IgG was injected in the first mouse (left
panel) without K16ApoE (SEQ ID NO: 22), while the second mouse
(right panel) received injection of the IgG mixed with K16ApoE (SEQ
ID NO: 22).
[0025] FIG. 6 shows the evaluation of the integrity of the BBB
after injection of K16ApoE (SEQ ID NO: 22). Each mouse (represented
by A through G) received an injection of K16ApoE (SEQ ID NO: 22),
followed by injection of .beta.-galactosidase at the indicated
times. Brain slices were made 4 hours after .beta.-galactosidase
injection and were followed by staining for activity of the enzyme.
A--.beta.-galactosidase was injected 1 minute after K16ApoE (SEQ ID
NO: 22) injection. B--.beta.-galactosidase was injected 5 minutes
after K16ApoE (SEQ ID NO: 22) injection. C--.beta.-galactosidase
was injected 10 minutes after K16ApoE (SEQ ID NO: 22) injection.
D--.beta.-galactosidase was injected 30 minutes after K16ApoE (SEQ
ID NO: 22) injection. E--.beta.-galactosidase was injected 1 hour
after K16ApoE (SEQ ID NO: 22) injection. F--.beta.-galactosidase
was injected 2 hours after K16ApoE (SEQ ID NO: 22) injection.
G--.beta.-galactosidase was injected 4 hours after K16ApoE (SEQ ID
NO: 22) injection. H--positive control (.beta.-galactosidase mixed
with K16ApoE (SEQ ID NO: 22) was injected, brain slices were made 4
hours after the injection and proceeded for staining for enzyme
activity).
[0026] FIG. 7 demonstrates the need for chemical linking of the K16
(SEQ ID NO: 4) and the ApoE peptide moieties for non-covalent
delivery across the BBB. Delivery of .beta.-galactosidase in brain
with K16 peptide (SEQ ID NO: 4) alone (A), with ApoE peptide only
(B), with K16 peptide (SEQ ID NO: 4)+ApoE peptide (C), and with
K16APoE peptide (SEQ ID NO: 22) (D).
[0027] FIG. 8 illustrates the testing mutant ApoE peptides for
their potential as non-covalent transporters of proteins across the
BBB. A--no peptide, no .beta.-gal; B--K16ApoE (SEQ ID NO:
22)+.beta.-gal; C--K16L3N7 (SEQ ID NO: 126)+.beta.-gal; D--K16L3L20
(SEQ ID NO: 127)+.beta.-gal; E--K16N7L20 (SEQ ID NO:
128)+.beta.-gal.
[0028] FIG. 9 shows a time course study of .beta.-galactosidase
delivery in mouse brain with K16ApoE (SEQ ID NO: 22).
A--.beta.-galactosidase, no peptide, 6 h; B--.beta.-galactosidase+
peptide, 1 h; C--.beta.-galactosidase+ peptide, 2 h;
D--.beta.-galactosidase+ peptide, 5 h; E--.beta.-galactosidase+
peptide, 10 h.
DETAILED DESCRIPTION
[0029] The peptides described herein can function as carrier
peptides. These peptides can associate with (e.g., non-covalently
bind) biologically active molecules and imaging agents to transport
the biologically active molecules and imaging agents across the
blood-brain barrier. In some cases, such transport may increase the
effectiveness of the biological molecules and imaging agents.
Carrier Peptides
[0030] Provided herein are carrier peptides having the following
sequence:
X.sub.n--[B].sub.m,
or a pharmaceutically acceptable salt, thereof, wherein: X is a
hydrophilic amino acid; B is a blood-brain barrier agent; n is an
integer from 4 to 50; and m is integer from 1 to 3.
[0031] In some embodiments, the blood-brain barrier is not
L-R-K-L-R-K-R-L-L-R-L-R-K-L-R-K-R-L-L-R (SEQ ID NO: 141).
[0032] A hydrophilic amino acid can be chosen from: arginine,
asparagine, aspartic acid, glutamic acid, glutamine, histidine,
lysine, serine, threonine, tyrosine, and combinations and
non-natural derivatives thereof. In some embodiments, a hydrophilic
amino acid can be chosen from lysine or a non-natural lysine
derivative, arginine or a non-natural arginine derivative, and
combinations thereof. In some embodiments, the hydrophilic amino
acid is lysine. Non-limiting examples of X.sub.n can include KKKK
(SEQ ID NO:1); KKKKKKKK (SEQ ID NO:2); KKKKKKKKKKKK (SEQ ID NO:3);
KKKKKKKKKKKKKKKK (SEQ ID NO:4); RRRR (SEQ ID NO:5); RRRRRRRR (SEQ
ID NO:6); RRRRRRRRRRRR (SEQ ID NO:7); RRRRRRRRRRRRRRRR (SEQ ID
NO:8); KRKR (SEQ ID NO:9); KKKR (SEQ ID NO:10); KKKRRRKKKRRR (SEQ
ID NO:11); and KKKKRRRRKKKKRRRR (SEQ ID NO:12).
[0033] The variable n is an integer ranging from 4 to 50 (e.g., 4,
6, 8, 10, 12, 16, 20, 24, 26, 28, 32, 36, 40, 42, 44, 48, and 50).
For example, n can range from 4 to 20. In some embodiments, n is
chosen from 4, 8, 12, 16, and 20. For example, n can be 16. In some
embodiments, m is 1.
[0034] A blood-brain barrier agent, as used herein, is any
polypeptide or non-polypeptide ligand that can cross the
blood-brain barrier. In some embodiments, a blood-brain barrier
agent has a cognate receptor on brain cells or can bind to such
receptors. In some embodiments, the blood-brain barrier agent
comprises a transferring-receptor binding site of a transferrin. In
some embodiments, the blood-brain barrier agent comprises a
receptor binding domain of an apolipoprotein. A receptor binding
domain of an apolipoprotein, for example, can be chosen from the
receptor binding domain of ApoA, ApoB, ApoC, ApoD, ApoE, ApoE2,
ApoE3, ApoE4, and combinations thereof. In some embodiments, the
receptor binding domain of an apoliprotein is chosen from the
receptor binding domain of ApoB and ApoE.
[0035] In some embodiments, the blood-brain barrier agent comprises
a sequence having at least 80% (e.g., at least 85%; at least 90%;
at least 92%; at least 95%; at least 98%; and at least 99%)
sequence identity to:
TABLE-US-00003 (SEQ ID NO: 13)
L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 14)
S-S-V-I-D-A-L-Q-Y-K-L-E-G-T-T-R-L-T-R-K-R-G-L-K-L-
A-T-A-L-S-L-S-N-K-F-V-E-G-S-H; (SEQ ID NO: 15)
Y-P-A-K-P-E-A-P-G-E-D-A-S-P-E-E-L-S-R-Y-Y-A-S-L-R-
H-Y-L-N-L-V-T-R-Q-R-Y*; (SEQ ID NO: 16)
A-K-P-E-A-P-G-E-D-A-S-P-E-E-L-S-R-Y-Y-A-S-L-R-H-Y-
L-N-L-V-T-R-Q-R-Y*; (SEQ ID NO: 17)
Y-P-S-D-P-D-N-P-G-E-D-A-P-A-E-D-L-A-R-Y-Y-S-A-L-R-
H-Y-I-N-L-I-T-R-Q-R-Y*; or (SEQ ID NO: 18)
A-P-L-E-P-V-Y-P-G-D-D-A-T-P-E-Q-M-A-Q-Y-A-A-E-L-R-
R-Y-I-N-M-L-T-R-P-R-Y*,
wherein Y* is tyrosine or a tyrosine derivative (e.g., an amidated
tyrosine). See, e.g., Ballantyne, G. H., Obesity Surgery,
16:651-658 2006.
[0036] In some embodiments, the blood-brain barrier agent includes
a polypeptide comprising the following sequence:
TABLE-US-00004 (SEQ ID NO: 29)
L-R-X1-R-X2-X3-X4-H-L-R-X5-X6-X7-K-R-L-X8-R-D-X9
wherein: X1 is selected from the group consisting of A, L, S, and
V; X2 is selected from the group consisting of L and M; X3 is
selected from the group consisting of A and S; X4 is selected from
the group consisting of N, S, and T; X5 is selected from the group
consisting of K and N; X6 is selected from the group consisting of
L, M, and V; X7 is selected from the group consisting of R and P;
X8 is selected from the group consisting of L and M; and X9 is
selected from the group consisting of A and L. Non-limiting
examples of a blood-brain barrier agents according to this sequence
include:
TABLE-US-00005 (SEQ ID NO: 13)
L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 30)
L-R-S-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 31)
L-R-V-R-M-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 32)
L-R-V-R-L-A-T-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 33)
L-R-V-R-L-A-S-H-L-R-K-L-P-K-R-L-L-R-D-A; (SEQ ID NO: 34)
L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-M-R-D-A; (SEQ ID NO: 35)
L-R-V-R-L-A-S-H-L-R-N-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 36)
L-R-V-R-L-A-S-H-L-R-K-V-R-K-R-L-L-R-D-A; (SEQ ID NO: 37)
L-R-V-R-M-S-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 38)
L-R-V-R-L-A-S-H-L-R-N-V-R-K-R-L-L-R-D-A; (SEQ ID NO: 39)
L-R-V-R-L-A-S-H-L-R-N-M-R-K-R-L-L-R-D-A; (SEQ ID NO: 40)
L-R-A-R-M-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 41)
L-R-V-R-L-S-S-H-L-R-K-L-R-K-R-L-M-R-D-A; (SEQ ID NO: 42)
L-R-S-R-L-A-S-H-L-R-K-L-R-K-R-L-M-R-D-A; (SEQ ID NO: 43)
L-R-V-R-L-S-S-H-L-P-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 44)
L-R-V-R-L-A-S-H-L-R-K-M-R-K-R-L-M-R-D-A; (SEQ ID NO: 45)
L-R-V-R-L-A-S-H-L-R-N-L-P-K-R-L-L-R-D-A; (SEQ ID NO: 129)
L-R-L-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-L; and (SEQ ID NO: 130)
L-R-V-R-L-A-N-H-L-R-K-L-R-K-R-L-L-R-D-L.
[0037] In some embodiments, the blood-brain barrier agent is less
than 100 amino acids in length (e.g., less than 90 amino acids in
length; less than 80 amino acids in length; less than 75 amino
acids in length; less than 70 amino acids in length; less than 65
amino acids in length; less than 62 amino acids in length; less
than 60 amino acids in length; less than 55 amino acids in length;
less than 50 amino acids in length; and less than 45 amino acids in
length).
[0038] "Percent sequence identity" refers to the degree of sequence
identity between any given reference sequence, e.g., SEQ ID NO:13,
and a candidate blood-brain barrier agent sequence. A candidate
sequence typically has a length that is from 80 percent to 200
percent of the length of the reference sequence (e.g., 82, 85, 87,
89, 90, 93, 95, 97, 99, 100, 105, 110, 115, 120, 130, 140, 150,
160, 170, 180, 190, or 200 percent of the length of the reference
sequence). A percent identity for any candidate nucleic acid or
polypeptide relative to a reference nucleic acid or polypeptide can
be determined as follows. A reference sequence (e.g., a nucleic
acid sequence or an amino acid sequence) is aligned to one or more
candidate sequences using the computer program ClustalW (version
1.83, default parameters), which allows alignments of nucleic acid
or polypeptide sequences to be carried out across their entire
length (global alignment). Chenna et al., Nucleic Acids Res.,
31(13):3497-500 (2003).
[0039] ClustalW calculates the best match between a reference and
one or more candidate sequences, and aligns them so that
identities, similarities and differences can be determined. Gaps of
one or more residues can be inserted into a reference sequence, a
candidate sequence, or both, to maximize sequence alignments. For
fast pairwise alignment of nucleic acid sequences, the following
default parameters are used: word size: 2; window size: 4; scoring
method: percentage; number of top diagonals: 4; and gap penalty: 5.
For multiple alignment of nucleic acid sequences, the following
parameters are used: gap opening penalty: 10. gap extension
penalty: 5.0; and weight transitions: yes. For fast pairwise
alignment of peptide sequences, the following parameters are used:
word size: 1; window size: 5; scoring method: percentage; number of
top diagonals: 5; gap penalty: 3. For multiple alignment of peptide
sequences, the following parameters are used: weight matrix:
blosum; gap opening penalty: 10. gap extension penalty: 0.5;
hydrophilic gaps: on; hydrophilic residues: Gly, Pro, Ser, Asn,
Asp, Gln, Glu, Arg, and Lys; residue-specific gap penalties: on.
The ClustalW output is a sequence alignment that reflects the
relationship between sequences. ClustalW can be run, for example,
at the Baylor College of Medicine Search Launcher site
(searchlauncher.bcm.tmc.edu/multi-align/multi-align.html) and at
the European Bioinformatics Institute site on the World Wide Web
(ebi.ac.uk/clustalw).
[0040] To determine percent identity of a candidate nucleic acid or
amino acid sequence to a reference sequence, the sequences are
aligned using ClustalW, the number of identical matches in the
alignment is divided by the length of the reference sequence, and
the result is multiplied by 100. It is noted that the percent
identity value can be rounded to the nearest tenth. For example,
78.11, 78.12, 78.13, and 78.14 are rounded down to 78.1, while
78.15, 78.16, 78.17, 78.18, and 78.19 are rounded up to 78.2.
[0041] The variable m is an integer from 1 to 3. In some
embodiments, m is 1.
[0042] In some embodiments, a carrier peptide can be chosen
from:
TABLE-US-00006 (SEQ ID NO: 19)
K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 20)
K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L- R-D-A; (SEQ ID
NO: 21) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-
K-R-L-L-R-D-A; (SEQ ID NO: 22)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-
R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 23)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
A-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 24)
K-K-K-K-S-S-V-I-D-A-L-Q-Y-K-L-E-G-T-T-R-L-T-R-K-R-
G-L-K-L-A-T-A-L-S-L-S-N-K-F-V-E-G-S-H; (SEQ ID NO: 25)
K-K-K-K-K-K-K-K-S-S-V-I-D-A-L-Q-Y-K-L-E-G-T-T-R-L-
T-R-K-R-G-L-K-L-A-T-A-L-S-L-S-N-K-F-V-E-G-S-H; (SEQ ID NO: 26)
K-K-K-K-K-K-K-K-K-K-K-K-S-S-V-I-D-A-L-Q-Y-K-L-E-G-
T-T-R-L-T-R-K-R-G-L-K-L-A-T-A-L-S-L-S-N-K-F-V-E-G- S-H; (SEQ ID NO:
27) K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-S-S-V-I-D-A-L-Q-Y-
K-L-E-G-T-T-R-L-T-R-K-R-G-L-K-L-A-T-A-L-S-L-S-N-K- F-V-E-G-S-H; and
(SEQ ID NO: 28) K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-S-S-V-I-D-
A-L-Q-Y-K-L-E-G-T-T-R-L-T-R-K-R-G-L-K-L-A-T-A-L-S-
L-S-N-K-F-V-E-G-S-H.
[0043] In some embodiments, a carrier peptide can be chosen
from:
TABLE-US-00007 (SEQ ID NO: 142)
[X].sub.n-L-R-X1-R-X2-X3-X4-H-L-R-X5-X6-X7-K-R-L-X8-R- D-X9
wherein: X is a hydrophilic amino acid; n is an integer from 4 to
20; X1 is selected from the group consisting of A, L, S, and V; X2
is selected from the group consisting of L and M; X3 is selected
from the group consisting of A and S; X4 is selected from the group
consisting of N, S, and T; X5 is selected from the group consisting
of K and N; X6 is selected from the group consisting of L, M, and
V; X7 is selected from the group consisting of R and P; X8 is
selected from the group consisting of L and M; and X9 is selected
from the group consisting of A and L. Non-limiting examples of a
blood-brain barrier agents according to this sequence include:
TABLE-US-00008 (SEQ ID NO: 19)
K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 20)
K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L- R-D-A; (SEQ ID
NO: 21) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-
K-R-L-L-R-D-A; (SEQ ID NO: 22)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-
R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 23)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
A-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 46)
K-K-K-K-L-R-S-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 47)
K-K-K-K-K-K-K-K-L-R-S-R-L-A-S-H-L-R-K-L-R-K-R-L-L- R-D-A; (SEQ ID
NO: 48) K-K-K-K-K-K-K-K-K-K-K-K-L-R-S-R-L-A-S-H-L-R-K-L-R-
K-R-L-L-R-D-A; (SEQ ID NO: 49)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-S-R-L-A-S-H-L-
R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 50)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-S-R-L-
A-S-H-L-R-K-L-R-K-R-L-L-R-D-A ; (SEQ ID NO: 51)
K-K-K-K-L-R-V-R-M-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 52)
K-K-K-K-K-K-K-K-L-R-V-R-M-A-S-H-L-R-K-L-R-K-R-L-L- R-D-A; (SEQ ID
NO: 53) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-M-A-S-H-L-R-K-L-R-
K-R-L-L-R-D-A; (SEQ ID NO: 54)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-M-A-S-H-L-
R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 55)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-M-
A-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 56)
K-K-K-K-L-R-V-R-L-A-T-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 57)
K-K-K-K-K-K-K-K-L-R-V-R-L-A-T-H-L-R-K-L-R-K-R-L-L- R-D-A; (SEQ ID
NO: 58) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-T-H-L-R-K-L-R-
K-R-L-L-R-D-A; (SEQ ID NO: 59)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-T-H-L-
R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 60)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
A-T-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 61)
K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-P-K-R-L-L-R-D-A; (SEQ ID NO: 62)
K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-P-K-R-L-L- R-D-A; (SEQ ID
NO: 63) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-P-
K-R-L-L-R-D-A; (SEQ ID NO: 64)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-
R-K-L-P-K-R-L-L-R-D-A; (SEQ ID NO: 65)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
A-S-H-L-R-K-L-P-K-R-L-L-R-D-A; (SEQ ID NO: 66)
K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-M-R-D-A; (SEQ ID NO: 67)
K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-M- R-D-A; (SEQ ID
NO: 68) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-
K-R-L-M-R-D-A; (SEQ ID NO: 69)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-
R-K-L-R-K-R-L-M-R-D-A; (SEQ ID NO: 70)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
A-S-H-L-R-K-L-R-K-R-L-M-R-D-A; (SEQ ID NO: 71)
K-K-K-K-L-R-V-R-L-A-S-H-L-R-N-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 72)
K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-N-L-R-K-R-L-L- R-D-A; (SEQ ID
NO: 73) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-N-L-R-
K-R-L-L-R-D-A; (SEQ ID NO: 74)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-
R-N-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 75)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
A-S-H-L-R-N-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 76)
K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-V-R-K-R-L-L-R-D-A; (SEQ ID NO: 77)
K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-V-R-K-R-L-L- R-D-A; (SEQ ID
NO: 78) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-V-R-
K-R-L-L-R-D-A; (SEQ ID NO: 79)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-
R-K-V-R-K-R-L-L-R-D-A; (SEQ ID NO: 80)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
A-S-H-L-R-K-V-R-K-R-L-L-R-D-A; (SEQ ID NO: 81)
K-K-K-K-L-R-V-R-M-S-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 82)
K-K-K-K-K-K-K-K-L-R-V-R-M-S-S-H-L-R-K-L-R-K-R-L-L- R-D-A; (SEQ ID
NO: 83) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-M-S-S-H-L-R-K-L-R-
K-R-L-L-R-D-A; (SEQ ID NO: 84)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-M-S-S-H-L-
R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 85)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-M-
S-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 86)
K-K-K-K-L-R-V-R-L-A-S-H-L-R-N-V-R-K-R-L-L-R-D-A; (SEQ ID NO: 87)
K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-N-V-R-K-R-L-L- R-D-A; (SEQ ID
NO: 88) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-N-V-R-
K-R-L-L-R-D-A; (SEQ ID NO: 89)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-
R-N-V-R-K-R-L-L-R-D-A; (SEQ ID NO: 90)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
A-S-H-L-R-N-V-R-K-R-L-L-R-D-A; (SEQ ID NO: 91)
K-K-K-K-L-R-V-R-L-A-S-H-L-R-N-M-R-K-R-L-L-R-D-A; (SEQ ID NO: 92)
K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-N-M-R-K-R-L-L- R-D-A; (SEQ ID
NO: 93) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-N-M-R-
K-R-L-L-R-D-A; (SEQ ID NO: 94)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-
R-N-M-R-K-R-L-L-R-D-A; (SEQ ID NO: 95)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
A-S-H-L-R-N-M-R-K-R-L-L-R-D-A; (SEQ ID NO: 96)
K-K-K-K-L-R-A-R-M-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 97)
K-K-K-K-K-K-K-K-L-R-A-R-M-A-S-H-L-R-K-L-R-K-R-L-L- R-D-A; (SEQ ID
NO: 98) K-K-K-K-K-K-K-K-K-K-K-K-L-R-A-R-M-A-S-H-L-R-K-L-R-
K-R-L-L-R-D-A; (SEQ ID NO: 99)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-A-R-M-A-S-H-L-
R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 100)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-A-R-M-
A-S-H-L-R-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 101)
K-K-K-K-L-R-V-R-L-S-S-H-L-R-K-L-R-K-R-L-M-R-D-A; (SEQ ID NO: 102)
K-K-K-K-K-K-K-K-L-R-V-R-L-S-S-H-L-R-K-L-R-K-R-L-M- R-D-A; (SEQ ID
NO: 103) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-S-S-H-L-R-K-L-R-
K-R-L-M-R-D-A; (SEQ ID NO: 104)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-S-S-H-L-
R-K-L-R-K-R-L-M-R-D-A; (SEQ ID NO: 105)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
S-S-H-L-R-K-L-R-K-R-L-M-R-D-A; (SEQ ID NO: 106)
K-K-K-K-L-R-S-R-L-A-S-H-L-R-K-L-R-K-R-L-M-R-D-A;
(SEQ ID NO: 107) K-K-K-K-K-K-K-K-L-R-S-R-L-A-S-H-L-R-K-L-R-K-R-L-M-
R-D-A; (SEQ ID NO: 108)
K-K-K-K-K-K-K-K-K-K-K-K-L-R-S-R-L-A-S-H-L-R-K-L-R- K-R-L-M-R-D-A;
(SEQ ID NO: 109) K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-S-R-L-A-S-H-L-
R-K-L-R-K-R-L-M-R-D-A; (SEQ ID NO: 110)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-S-R-L-
A-S-H-L-R-K-L-R-K-R-L-M-R-D-A; (SEQ ID NO: 111)
K-K-K-K-L-R-V-R-L-S-S-H-L-P-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 112)
K-K-K-K-K-K-K-K-L-R-V-R-L-S-S-H-L-P-K-L-R-K-R-L-L- R-D-A; (SEQ ID
NO: 113) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-S-S-H-L-P-K-L-R-
K-R-L-L-R-D-A; (SEQ ID NO: 114)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-S-S-H-L-
P-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 115)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
S-S-H-L-P-K-L-R-K-R-L-L-R-D-A; (SEQ ID NO: 116)
K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-M-R-K-R-L-M-R-D-A; (SEQ ID NO: 117)
K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-M-R-K-R-L-M- R-D-A; (SEQ ID
NO: 118) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-M-R-
K-R-L-M-R-D-A; (SEQ ID NO: 119)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-
R-K-M-R-K-R-L-M-R-D-A; (SEQ ID NO: 120)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
A-S-H-L-R-K-M-R-K-R-L-M-R-D-A; (SEQ ID NO: 121)
K-K-K-K-L-R-V-R-L-A-S-H-L-R-N-L-P-K-R-L-L-R-D-A; (SEQ ID NO: 122)
K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-N-L-P-K-R-L-L- R-D-A; (SEQ ID
NO: 123) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-N-L-P-
K-R-L-L-R-D-A; (SEQ ID NO: 124)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-
R-N-L-P-K-R-L-L-R-D-A; (SEQ ID NO: 125)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
A-S-H-L-R-N-L-P-K-R-L-L-R-D-A; (SEQ ID NO: 131)
K-K-K-K-L-R-L-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-L; (SEQ ID NO: 132)
K-K-K-K-K-K-K-K-L-R-L-R-L-A-S-H-L-R-K-L-R-K-R-L-L- R-D-L; (SEQ ID
NO: 133) K-K-K-K-K-K-K-K-K-K-K-K-L-R-L-R-L-A-S-H-L-R-K-L-R-
K-R-L-L-R-D-L; (SEQ ID NO: 134)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-L-R-L-A-S-H-L-
R-K-L-R-K-R-L-L-R-D-L; (SEQ ID NO: 135)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-L-R-L-
A-S-H-L-R-K-L-R-K-R-L-L-R-D-L; (SEQ ID NO: 136)
K-K-K-K-L-R-V-R-L-A-N-H-L-R-K-L-R-K-R-L-L-R-D-L; (SEQ ID NO: 137)
K-K-K-K-K-K-K-K-L-R-V-R-L-A-N-H-L-R-K-L-R-K-R-L-L- R-D-L; (SEQ ID
NO: 138) K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-N-H-L-R-K-L-R-
K-R-L-L-R-D-L; (SEQ ID NO: 139)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-N-H-L-
R-K-L-R-K-R-L-L-R-D-L; or (SEQ ID NO: 140)
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-
A-N-H-L-R-K-L-R-K-R-L-L-R-D-L.
Complexes
[0044] Also provided herein are complexes having a biologically
active molecule or an imaging agent associated with a carrier
peptide as described herein. In some embodiments, the biologically
active molecule or imaging agent is non-covalently bound to the
carrier peptide.
[0045] As used herein, a "biologically active molecule" includes
any molecule which, if transported across the blood-brain barrier,
can have a biological effect. Examples of biologically active
molecules include polypeptides, which include functional domains of
biologically active molecules, particular examples include growth
factors, enzymes, transcription factors, toxins, antigenic peptides
(as for vaccines), antibodies, and antibody fragments. For example,
brain derived neurotrophic factor, fibroblast growth factor (e.g.,
(FGF)-2 or multiple FGFs), nerve growth factor, neurotrophin (e.g.,
NT-3 and NT-4/5), glial derived neurotrophic factor, ciliary
neurotrophic factor, neurturin, neuregulins, interleukins,
transforming growth factor (e.g., TGF-.alpha. and TGF-.beta.),
vasoactibe intestinal peptide, epidermal growth factor (EGF),
erythropoietin, heptocytel growth factor, platelet derived growth
factor, artemin, persephin, netrins, cardiotrophin-1, stem cell
factor, midkine, pleiotrophin, bone morphogenic proteins, saposins,
semaporins, leukemia inhibitory factor, anti-A.beta., anti-HER2,
anti-EGF, anti-nogo A, anti-TRAIL (tumor necrosis factor-related
apoptosis-inducing ligand), anti-.alpha.-synuclein, anti-htt,
anti-prion, anti-West Nile virus, .alpha.L-iduronidase,
iduronate-2-sulfatase, N-acetyl-galactosamine-6-sulfatase,
arylsulfatase B, acid a-glucosidase, and acid sphingomyelinase
(See, Pardridge, W. M., Bioconjug. Chem. 19(7): 1327-38 2008).
Additional examples of biologically active molecules include
oligonucleotides, such as natural or engineered plasmids, coding
DNA sequences, antisense DNA sequences, mRNAs, antisense RNA
sequences, RNA is, and siRNAs; carbohydrates; lipids; and
glycolipids.
[0046] Further examples of biologically active molecules include
small molecules, including therapeutic agents, in particular those
with low blood-brain barrier permeability. Some examples of these
therapeutic agents include cancer drugs, such as daunorubicin and
toxic chemicals which, because of the lower dosage that can be
administered by this method, can now be more safely administered.
For example, a therapeutic agent can include bevacizumab,
irinotecan, zoledronate, and temozolomide. In another embodiment,
the therapeutic agent can include a broad-spectrum antibiotic
(e.g., cefotaxime, ceftriaxone, ampicillin and vancomycin); an
antiviral agent (e.g., acyclovir); acetazolamide; carbamazepine;
clonazepam; clorazepate dipotassium; diazepam; divalproex sodium;
ethosuximide; felbamate; fosphenytoin sodium; gabapentin;
lamotrigine; levetiracetam; lorazepam; oxcarbazepine;
phenobarbital; phenytoin; phenytoin sodium; pregabalin; primidone;
tiagabine hydrochloride; topiramate; trimethadione; valproic acid;
zonisamide; copaxone; tysabri; novantrone; donezepil HCL;
rivastigmine; galantamine; memantine; levodopa; carbidopa;
parlodel, permax, requip, mirapex; symmetrel; artane; cogentin;
eldepryl; and deprenyl.
[0047] Numerous other examples of biologically active molecules
will be apparent to the skilled artisan.
[0048] Yet another example of a biologically active molecule is an
antigenic peptide. Antigenic peptides can be administered to
provide immunological protection when imported by cells involved in
the immune response. Other examples include immunosuppressive
peptides (e.g., peptides that block autoreactive T cells, which
peptides are known in the art).
[0049] Polypeptides from a few amino acids to about a thousand
amino acids can be used. In some embodiments, the size range for
polypeptides is from a few amino acids to about 250 amino acids
(e.g., about 3 to about 250 amino acids; about 20 to about 250
amino acids; about 50 to about 250 amino acids; about 100 to about
250 amino acids; about 150 to about 250 amino acids; about 3 amino
acids to about 200 amino acids; about 3 amino acids to about 150
amino acids; about 3 amino acids to about 175 amino acids; about 3
amino acids to about 125 amino acids; about 25 amino acids to about
200 amino acids; about 50 amino acids to about 150 amino acids; and
about 75 amino acids to about 225 amino acids). For any molecule,
size ranges can be up to about a molecular weight of about 1
million. In some embodiments, the size ranges up to a molecular
weight of about 25,000, and in particular embodiments, the size
ranges can be up to a molecular weight of about 3,000.
[0050] By "antisense" it is meant a non-enzymatic nucleic acid
molecule that binds to target RNA by means of RNA-RNA or RNA-DNA or
RNA-PNA (protein nucleic acid; Egholm et al., 1993 Nature 365, 566)
interactions and alters the activity of the target RNA (for a
review, see Stein and Cheng, 1993 Science 261, 1004; Agrawal et
al., U.S. Pat. No. 5,591,721; Agrawal, U.S. Pat. No. 5,652,356).
Typically, antisense molecules will be complementary to a target
sequence along a single contiguous sequence of the antisense
molecule. However, in certain embodiments, an antisense molecule
may bind to a substrate such that the substrate molecule forms a
loop, and/or an antisense molecule may bind such that the antisense
molecule forms a loop. Thus, the antisense molecule may be
complementary to two (or even more) non-contiguous substrate
sequences or two (or even more) non-contiguous sequence portions of
an antisense molecule may be complementary to a target sequence or
both.
[0051] RNA interference (RNAi) and short intervening RNA (siRNA)
sequences can be used to modulate (e.g., inhibit) gene expression
(see, e.g., Elbashir et al., 2001, Nature, 411, 494 498; and Bass,
2001, Nature, 411, 428 429; Bass, 2001, Nature, 411, 428 429; and
Kreutzer et al., International PCT Publication No. WO 00/44895;
Zernicka-Goetz et al., International PCT Publication No. WO
01/36646; Fire, International PCT Publication No. WO 99/32619;
Plaetinck et al., International PCT Publication No. WO 00/01846;
Mello and Fire, International PCT Publication No. WO 01/29058;
Deschamps-Depaillette, International PCT Publication No. WO
99/07409; and Li et al., International PCT Publication No. WO
00/44914). In one embodiment, a siRNA molecule comprises a double
stranded RNA wherein one strand of the RNA is complimentary to the
RNA of interest. In another embodiment, a siRNA molecule comprises
a double stranded RNA wherein one strand of the RNA comprises a
portion of a sequence of an RNA of interest. In yet another
embodiment, a siRNA molecule of the invention comprises a double
stranded RNA wherein both strands of RNA are connected by a
non-nucleotide linker. Alternately, a siRNA molecule of the
invention comprises a double stranded RNA wherein both strands of
RNA are connected by a nucleotide linker, such as a loop or stem
loop structure.
[0052] The term "antibody" as used herein refers to immunoglobulin
molecules and immunologically active portions of immunoglobulin
molecules (i.e., molecules that contain an antigen binding site
that specifically binds to a peptide). An antibody can be a
monoclonal antibody, a polyclonal antibody, a humanized antibody, a
fully human antibody, a single chain antibody, a chimeric antibody,
or a fragment thereof. The term "antibody fragment" of a full
length antibody refers to one or more fragments of a full-length
antibody that retain the ability to specifically bind to a target
of interest.
[0053] An imaging agent, as used herein, can be any chemical or
substance which is used to provide the signal or contrast in
imaging. The signal enhancing domain can be an organic molecule,
metal ion, salt or chelate, particle (particularly iron particle),
or labeled peptide, protein, polymer or liposome.
[0054] In some embodiments, the imaging agent is a physiologically
compatible metal chelate compound consisting of one or more cyclic
or acyclic organic chelating agents complexed to one or more metal
ions with atomic numbers 21-29, 42, 44, or 57-83.
[0055] For x-ray imaging, the imaging agent may consist of
iodinated organic molecules or chelates of heavy metal ions of
atomic numbers 57 to 83. In some embodiments, the imaging agent is
.sup.125I-IgG. Examples of suitable compounds are described in M.
Sovak, ed., "Radiocontrast Agents," Springer-Verlag, pp. 23-125
(1984) and U.S. Pat. No. 4,647,447.
[0056] For ultrasound imaging, the imaging agent can consist of
gas-filled bubbles such as Albunex, Echovist, or Levovist, or
particles or metal chelates where the metal ions have atomic
numbers 21-29, 42, 44 or 57-83. Examples of suitable compounds are
described in Tyler et al., Ultrasonic Imaging, 3, pp. 323-29 (1981)
and D. P. Swanson, "Enhancement Agents for Ultrasound:
Fundamentals," Pharmaceuticals in Medical Imaging, pp. 682-87.
(1990).
[0057] For nuclear radiopharmaceutical imaging or radiotherapy, the
imaging agent can consist of a radioactive molecule. In some
embodiments, the chelates of Tc, Re, Co, Cu, Au, Ag, Pb, Bi, In,
and Ga can be used. In some embodiments, the chelates of Tc-99m can
be used. Examples of suitable compounds are described in Rayudu
GVS, Radiotracers for Medical Applications, I, pp. 201 and D. P.
Swanson et al., ed., Pharmaceuticals in Medical Imaging, pp.
279-644 (1990).
[0058] For ultraviolet/visible/infrared light imaging, the imaging
agent can consist of any organic or inorganic dye or any metal
chelate.
[0059] For MRI, the imaging agent can consist of a metal-ligand
complex of a paramagnetic form of a metal ion with atomic numbers
21-29, 42, 44, or 57-83. In some embodiments, the paramagnetic
metal is chosen from: Gd(III), Mn(II and III), Cr(III), Cu(II),
Dy(III), Tb(III), Ho(III), Er(III) and Eu(III). Many suitable
chelating ligands for MRI agents are known in the art. These can
also be used for metal chelates for other forms of biological
imaging. For example, an imaging agent can include:
##STR00001##
[0060] "Associated with", as used herein, is meant that the
biologically active molecule or imaging agent is conjugated to the
carrier peptide in such a manner that when the carrier peptide
crosses the blood-brain barrier, the molecule or agent is also
imported. In certain embodiments, the biologically active molecule
or imaging agent is non-covalently bound to the carrier peptide.
For example, the biologically active molecule and the carrier
peptide may be associated through electrostatic interactions. In
other embodiments, the carrier peptide may be covalently bound,
either directly or indirectly (e.g., through a linker), to the
biologically active molecule or imaging agent.
[0061] A linker can be any moiety suitable for linking a carrier
peptide to a biologically active molecule. A linker can be bound at
the C-terminus, the N-terminus, or both, of a carrier peptide.
Additionally, a linker can be bound to the side chain of a carrier
peptide. If a carrier peptide is bound to multiple linkers, each
linker can be different. A linker can be covalently linked to a
side chain of an amino acid, e.g., lysine, glutamine, cysteine,
methionine, glutamate, aspartate, asparagine.
[0062] In some embodiments an amino acid side chain can serve as
the linker. For example the epsilon amino group
(.epsilon.-NH.sub.2) can be used to conjugate to a carrier for
instance through an amide or thiourea linkage. Similarly the delta
amino group of ornithine (orn), the gamma amino group of
diaminobutyric acid (dab), or the beta amino group of diamino
proprionic acid (dpr) can also act as linkers. These amino acids
may be at the C- or N-terminus of the carrier peptide or they may
be positioned within the carrier peptide sequence.
[0063] The complex composed of a biologically active molecule or
imaging agent and a carrier peptide can be prepared by any method
known by those having ordinary skill in the art. In some
embodiments, the carrier peptide and the biologically active
molecule or imaging agent are combined, incubated at room
temperature, and then used. For example, solutions can be prepared
of the delivery peptide (K16ApoE (SEQ ID NO: 22)) and IgG in PBS
(phosphate buffered saline) or OptiMem (commercially available) or
cell culture media without serum in desired concentrations. The
delivery peptide and IgG can be mixed in the desired ratios and
then incubated at room temperature for 30-60 minute. Following
incubation, the mixture is ready for injection/delivery.
[0064] Combinations of the biologically active molecule and the
carrier peptide can be prepared at a variety of molar ratios. For
example, a molar ratio of biologically active molecule to carrier
peptide can range from about 1:1 to about 1:200 (e.g., 1:2; 1:5;
1:8; 1:10; 1:25; 1:30; 1:40; 1:45; 1:50; 1:60; 1:65; 1:70; 1:75;
1:80; 1:90; 1:100; 1:125; 1:135; 1:145; 1:150; 1:175; and 1:190).
In some embodiments, a molar excess of carrier peptide to
biologically active molecule is used. For example, the molar ratio
of biologically active molecule to carrier peptide can range from
about 1:20 to about 1:100 (e.g, 1:50 to about 1:90). In some cases,
the ratio can be 1:70.
[0065] The term "pharmaceutically-acceptable salt" refers to salts
which possess toxicity profiles within a range that affords utility
in pharmaceutical applications. Pharmaceutically unacceptable salts
may nonetheless possess properties such as high crystallinity,
which may render them useful, for example in processes of
synthesis, purification or formulation of compounds described
herein. In general the useful properties of the compounds described
herein do not depend critically on whether the compound is or is
not in a salt form, so unless clearly indicated otherwise (such as
specifying that the compound should be in "free base" or "free
acid" form), reference in the specification to a carrier peptide or
a complex comprising a carrier peptide should be understood as
encompassing salt forms of the compound, whether or not this is
explicitly stated.
[0066] Suitable pharmaceutically-acceptable acid addition salts may
be prepared from an inorganic acid or from an organic acid.
Examples of inorganic acids include hydrochloric, hydrobromic,
hydriodic, nitric, carbonic, sulfuric, and phosphoric acids.
Appropriate organic acids may be selected from aliphatic,
cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and
sulfonic classes of organic acids, examples of which include
formic, acetic, propionic, succinic, glycolic, gluconic, lactic,
malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric,
pyruvic, aspartic, glutamic, benzoic, anthranilic,
4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic),
methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic,
trifluoromethanesulfonic, 2-hydroxyethanesulfonic,
p-toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic,
alginic, .beta.-hydroxybutyric, salicylic, galactaric and
galacturonic acid. Examples of pharmaceutically unacceptable acid
addition salts include, for example, perchlorates and
tetrafluoroborates.
[0067] Suitable pharmaceutically acceptable base addition salts
include, for example, metallic salts including alkali metal,
alkaline earth metal and transition metal salts such as, for
example, calcium, magnesium, potassium, sodium and zinc salts.
Pharmaceutically acceptable base addition salts also include
organic salts made from basic amines such as, for example,
N,N-dibenzylethylenediamine, chloroprocaine, choline,
diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and
procaine. Examples of pharmaceutically unacceptable base addition
salts include lithium salts and cyanate salts.
[0068] All of these salts may be prepared by conventional means
from the corresponding carrier peptide or complex by reacting, for
example, the appropriate acid or base with a carrier peptide or
complex as described herein. Preferably the salts are in
crystalline form, and preferably prepared by crystallization of the
salt from a suitable solvent. A person skilled in the art will know
how to prepare and select suitable salt forms for example, as
described in Handbook of Pharmaceutical Salts: Properties,
Selection, and Use By P. H. Stahl and C. G. Wermuth (Wiley-VCH
2002).
Methods of Use
[0069] Also provided herein are methods of using carrier peptides
to transport a biologically active molecule or imaging agent across
the blood-brain barrier of a subject. The method can include
administering to the subject a complex having a biologically active
molecule or imaging agent associated with a carrier peptide, or a
pharmaceutically acceptable salt, as described herein.
[0070] A subject can include both mammals and non-mammals. Mammals
include, for example, humans; nonhuman primates, e.g. apes and
monkeys; cattle; horses; sheep; rats; mice; pigs; and goats.
Non-mammals include, for example, fish and birds.
[0071] Transporting a biologically active molecule can include
importing the molecule across the blood-brain barrier.
[0072] Further provided herein is a method of treating a brain
disorder in a subject. The method can include administering to the
subject a complex comprising a biologically active agent associated
with a carrier peptide, as described herein. In some embodiments,
the biologically active molecule is a therapeutic agent. In some
embodiments, the brain disorder is chosen from: meningitis,
epilepsy, multiple sclerosis, neuromyelitis optica, late-stage
neurological trypanosomiasis, Parkinson's, progressive multifocal
leukoencephalopathy, De Vivo disease, Alzheimer's disease, HIV
Encephalitis, and cancer.
[0073] In some embodiments, the brain disorder is a brain cancer,
for example astrocytoma, medulloblastoma, glioma, ependymoma,
germinoma (pinealoma), glioblastoma multiform, oligodendroglioma,
schwannoma, retinoblastoma, and congenital tumors; or a cancer of
the spinal cord, e.g., neurofibroma, meningioma, glioma, and
sarcoma.
[0074] This disclosure also provides a method of imaging the
central nervous system of a subject. In some embodiments, the
method can include administering to the subject a complex
comprising an imaging agent associated with a carrier peptide, as
described herein, and imaging the central nervous system of the
subject.
[0075] The complex can be administered by any route, e.g., IV,
intramuscular, SC, oral, intranasal, inhalation, transdermal, and
parenteral.
[0076] The complex can be formulated with a pharmaceutically
acceptable carrier selected on the basis of the selected route of
administration and standard pharmaceutical practice. The complex
may be formulated into dosage forms according to standard practices
in the field of pharmaceutical preparations. See Alphonso Gennaro,
ed., Remington's Pharmaceutical Sciences, 18th Edition (1990), Mack
Publishing Co., Easton, Pa. Suitable dosage forms may comprise, for
example, tablets, capsules, solutions, parenteral solutions,
troches, suppositories, or suspensions.
[0077] For parenteral administration, the complex may be mixed with
a suitable carrier or diluent such as water, an oil (particularly a
vegetable oil), ethanol, saline solution, aqueous dextrose
(glucose) and related sugar solutions, glycerol, or a glycol such
as propylene glycol or polyethylene glycol. Solutions for
parenteral administration preferably contain a water soluble salt
of the complex. Stabilizing agents, antioxidant agents and
preservatives may also be added. Suitable antioxidant agents
include sulfite, ascorbic acid, citric acid and its salts, and
sodium EDTA. Suitable preservatives include benzalkonium chloride,
methyl- or propyl-paraben, and chlorbutanol. The composition for
parenteral administration may take the form of an aqueous or
non-aqueous solution, dispersion, suspension or emulsion.
[0078] For oral administration, the complex may be combined with
one or more solid inactive ingredients for the preparation of
tablets, capsules, pills, powders, granules or other suitable oral
dosage forms. For example, the complex may be combined with at
least one excipient such as fillers, binders, humectants,
disintegrating agents, solution retarders, absorption accelerators,
wetting agents absorbents or lubricating agents.
[0079] The specific dose of a complex will, of course, be
determined by the particular circumstances of the individual
patient including the size, weight, age and sex of the patient, the
nature and stage of the disease being treated, the aggressiveness
of the disease disorder, and the route of administration of the
compound.
Pharmaceutical Compositions
[0080] Provided herein are pharmaceutical compositions comprising a
biologically active molecule or imaging agent associated with a
carrier peptide. In some embodiments, the biologically active
molecule or imaging agent is non-covalently bound to the carrier
peptide.
[0081] The pharmaceutical compositions provided herein contain a
biologically active molecule or imaging agent associated with a
carrier peptide in an amount that results in transportation of the
biologically active molecule or imaging agent across the
blood-brain barrier, and a pharmaceutically acceptable carrier.
Pharmaceutical carriers suitable for administration of the
compounds provided herein include any such carriers known to those
skilled in the art to be suitable for the particular mode of
administration.
[0082] The compositions can be, in one embodiment, formulated into
suitable pharmaceutical preparations such as solutions,
suspensions, tablets, dispersible tablets, pills, capsules,
powders, sustained release formulations or elixirs, for oral
administration or in sterile solutions or suspensions for
parenteral administration and intraperitoneal injection, as well as
transdermal patch preparation, dry powder inhalers, and ointments
(see, e.g., Ansel Introduction to Pharmaceutical Dosage Forms,
Fourth Edition 1985, 126).
[0083] The concentration of the biologically active molecule or
imaging agent associated with a carrier peptide in the
pharmaceutical composition will depend on absorption, inactivation
and excretion rates of the compounds, the physicochemical
characteristics of the compounds, the dosage schedule, and amount
administered as well as other factors known to those of skill in
the art.
[0084] The pharmaceutical composition may be administered at once,
or may be divided into a number of smaller doses to be administered
at intervals of time. It is understood that the precise dosage and
duration of treatment is a function of the disease being treated
and may be determined empirically using known testing protocols or
by extrapolation from in vivo or in vitro test data. It is to be
noted that concentrations and dosage values may also vary with the
severity of the condition to be alleviated. It is to be further
understood that for any particular subject, specific dosage
regimens should be adjusted over time according to the individual
need and the professional judgment of the person administering or
supervising the administration of the compositions, and that the
concentration ranges set forth herein are exemplary only and are
not intended to limit the scope or practice of the claimed
compositions.
[0085] The pharmaceutical compositions are provided for
administration to humans and animals in unit dosage forms, such as
tablets, capsules, pills, powders, granules, sterile parenteral
solutions or suspensions, and oral solutions or suspensions, and
oil-water emulsions containing suitable quantities of the compounds
or pharmaceutically acceptable derivatives thereof. The
pharmaceutically therapeutically active compounds and derivatives
thereof are, in one embodiment, formulated and administered in
unit-dosage forms or multiple-dosage forms. Unit-dose forms as used
herein refers to physically discrete units suitable for human and
animal subjects and packaged individually as is known in the art.
Each unit-dose contains a predetermined quantity of the
therapeutically active compound sufficient to produce the desired
therapeutic effect, in association with the required pharmaceutical
carrier, vehicle or diluent. Examples of unit-dose forms include
ampoules and syringes and individually packaged tablets or
capsules. Unit-dose forms may be administered in fractions or
multiples thereof. A multiple-dose form is a plurality of identical
unit-dosage forms packaged in a single container to be administered
in segregated unit-dose form. Examples of multiple-dose forms
include vials, bottles of tablets or capsules or bottles of pints
or gallons. Hence, multiple dose form is a multiple of unit-doses
which are not segregated in packaging.
[0086] Liquid pharmaceutically administrable compositions can, for
example, be prepared by dissolving, dispersing, or otherwise mixing
an active compound as defined above and optional pharmaceutical
adjuvants in a carrier, such as, for example, water, saline,
aqueous dextrose, glycerol, glycols, ethanol, and the like, to
thereby form a solution or suspension. If desired, the
pharmaceutical composition to be administered may also contain
minor amounts of nontoxic auxiliary substances such as wetting
agents, emulsifying agents, solubilizing agents, pH buffering
agents and the like, for example, acetate, sodium citrate,
cyclodextrine derivatives, sorbitan monolaurate, triethanolamine
sodium acetate, triethanolamine oleate, and other such agents.
[0087] Actual methods of preparing such dosage forms are known, or
will be apparent, to those skilled in this art; for example, see
Remington's Pharmaceutical Sciences, Mack Publishing Company,
Easton, Pa., 15th Edition, 1975.
[0088] Dosage forms or compositions containing a biologically
active molecule or imaging agent associated with a carrier peptide
in the range of 0.005% to 100% with the balance made up with a
non-toxic carrier may be prepared. Methods for preparation of these
compositions are known to those skilled in the art. The
contemplated compositions may contain 0.001%-100% active
ingredient, in one embodiment 0.1-95%, in another embodiment
75-85%.
Kits
[0089] Also provided herein are kits. Typically, a kit includes a
carrier peptide, as described previously. In some embodiments, a
kit includes a carrier peptide and a biologically active molecule
and/or imaging agent. In certain embodiments, a kit can include one
or more delivery systems, e.g., for a biologically active molecule,
imaging agent, carrier peptide, or any combination thereof, and
directions for use of the kit (e.g., instructions for administering
to a subject). In certain embodiments, a kit can include a
biologically active molecule and/or an imaging agent, a carrier
peptide, and/or a complex of a biologically active molecule or
imaging agent and a carrier peptide. In some embodiments, the kit
can include a carrier peptide and a label that indicates that the
contents are to be administered to a subject with a biologically
active molecule or imaging agent.
EXAMPLES
General
Materials:
[0090] All mice used (B6SJLF1) were female and were purchased from
the Jackson Laboratories. Mice were maintained and used following
an IRB-approved protocol. Bacterial .beta.-galactosidase was
purchased from Calbiochem (Catalog #345788). Human IgG and IgM were
purchased from Sigma (Product Numbers I 4506 and 18260
respectively). The 4G8 monclonal antibody (cat# SIG-39220) was
purchased from Covance (Emeryville, Calif.). LDL receptor antibody
was from abcam (Cat # ab30532).
[0091] All peptides were synthesized at the Mayo Proteomic Core
Facility.
Preparation of Peptide-Protein Complex for Delivery in the
Brain:
[0092] Required amount of the peptide and protein were mixed in a
final volume of 300 .mu.L PBS (phosphate buffered saline), and
incubated at room temperature for 60 minutes. The mixture was
vortexed for a few seconds, every fifteen minutes during the
incubation period.
[0093] The mixture was injected intravenously as a bolus into the
lumen of the femoral vein. This was accomplished using a heat
pulled PESO catheter. At the conclusion of the experiment, the
mouse was euthanized with a lethal dose of sodium pentobarbital.
Each mouse was perfused with 10 mL PBS. This perfusion was
accomplished through the standard trans cardial method. The brain
was removed from the skull and positioned to make an initial
coronal slice at -2.0 mm bregma. Subsequently, 25 .mu.m coronal
sections were cut on a cryostat and placed on charged slides for
staining of .beta.-galactosidase activity.
Staining for Beta-Galactosidase Enzyme Activity:
[0094] Evaluation of .beta.-galactosidase enzymatic activity was
accomplished by an initial 15 minute fixation of the brain sections
in 0.25% glutaraldehyde. The slides were washed with 3 changes of
PBS for 5 minutes each and then rinsed in distilled water for 5
minutes. The brain sections were incubated in X-Gal (0.2%) working
solution, pH 7.38, for 18 hours at 37.degree. C. in covered
containers. Following this incubation the sections were dehydrated
and coverslips were applied.
Imaging by microSPECT:
[0095] Micro SPECT/CT experiments were conducted on a Gamma Medica
X SPECT System (GE Healthcare). Human IgG (Sigma) and IgM (Sigma)
were labeled to a high specific activity using the Chloramine-T
method. 80 .mu.g (500 .mu.Ci) of each immunoglobulin (corresponds
to 0.53 nanomole of IgG and 0.13 nanomole of IgM assuming molecular
weights of 150 Kd and 600 Kd for IgG and IgM, respectively) was
mixed with 70-fold molar excess of K16ApoE (SEQ ID NO: 22) (as
required for experiment) for 1 hour at room temperature and was
administered in each mouse through the use of a catheter in the
femoral vein. Immediately subsequent to the intravenous bolus
injection, the mice were imaged every hour for a total of 6 hours.
At the completion of the 6 hour time point, each mouse was
euthanized and the systemic blood supply was transcardially
perfused with 10 mL phosphate buffered saline, and imaged after 30
minutes.
Example 1--Delivery of Radiolabeled IgG Across the BBB
[0096] The delivery of radiolabeled IgG across the BBB in different
brain regions in mice with and without the peptide K.sub.16ApoE
(SEQ ID NO:22) was evaluated. In addition, the integrity of the BBB
after delivery of IgG with K.sub.16ApoE (SEQ ID NO: 22) was
examined. 3 .mu.mol of .sup.125I-IgG were mixed with varying
amounts of the peptide K.sub.16ApoE (SEQ ID NO: 22) (0-55 .mu.mol),
and the mixture injected intravenously into the mice. .sup.131I-IgG
not complexed with the peptide was injected into the same animals
at 59 minutes and allowed to circulate for 1 minute subsequent to
the initial femoral vein injection of .sup.125I-IgG+K.sub.16ApoE
(SEQ ID NO: 22). Uptake of .sup.125I-IgG and .sup.131I-IgG were
measured in different areas of the brain after 60 minutes.
TABLE-US-00009 TABLE 1 +ApoE, +ApoE, +ApoE, +ApoE, IgG, 3 .mu.mol 8
.mu.mol 16 .mu.mol 32 .mu.mol 55 .mu.mol PS .times. 10.sup.6
(ml/g/s) Cortex 0.13 +- 0.02 0.30 0.47 9.58 15.30 Caudate 0.09 +-
0.01 0.35 0.86 16.65 22.60 Hippo 0.17 +- 0.02 0.58 1.05 12.52 20.90
Thalamus 0.13 +- 0.02 0.29 1.37 19.60 21.00 Brainstem 0.20 +- 0.02
0.45 1.64 22.90 18.40 Cerebellum 0.15 +- 0.02 0.48 0.72 13.43 21.60
Vp (ul/g) Cortex 13.53 +- 0.98 21.39 21.22 16.41 25.59 Caudate 8.53
+- 0.52 14.44 11.67 12.89 20.10 Hippo 15.13 +- 2.35 17.49 16.95
12.67 21.83 Thalamus 13.79 +- 1.09 19.96 21.00 18.34 26.92
Brainstem 22.32 +- 1.51 19.02 31.50 20.54 34.60 Cerebellum 20.79 +-
1.24 21.28 23.74 19.79 24.31 N (no of mice) 4 2 2 2 1
PS values reflect the amount of .sup.125I-IgG that has crossed the
BBB, whereas Vp values indicate the amount of .sup.131I-IgG at the
BBB but which has not crossed the BBB.
[0097] As shown in Table 1, the PS values with IgG alone are very
small for all the brain regions, indicating very little transport
of the IgG across the BBB. However, the values increased
significantly (.about.100-fold at 55 .mu.mol of K.sub.16ApoE (SEQ
ID NO: 22)) with increasing amounts of the delivery peptide.
[0098] On the other hand, the Vp values remained virtually
unchanged in all the brain regions examined, indicating
.sup.131I-IgG failed to cross the BBB (since it was not complexed
with the peptide), and attesting to the notion that the BBB was not
damaged due to prior exposure to the peptide (during delivery of
.sup.125I-IgG complexed with K.sub.16ApoE (SEQ ID NO: 22)).
Example 2--Delivery of Alexa-IgG Assisted by K.sub.16ApoE (SEQ ID
NO: 22) into Brain
[0099] In this experiment, AlexaIgG488 was injected into mice with
or without mixing with K.sub.16ApoE peptide (SEQ ID NO:22). Brain
sections were made 1 hour after delivery. As shown in FIG. 1, the
complexed agent shows significantly brighter contrast and
enhancement of brain structures compared to the uncomplexed
AlexaIgG488.
Example 3--Delivery of ApoE Peptide (without K.sub.16 Moiety)
Across the BBB and Binding of Peptide to LDL Receptors
[0100] The experiments will evaluate the ApoE peptide (without the
K16 moiety (SEQ ID NO: 4)) crossing of the BBB and whether it will
bind/localize to LDL receptors (LDLR) expressed in the brain. An
FITC-labeled ApoE peptide will be synthesized and injected into
mice. Brain specimens will be collected after 1 hour following
injection, and slides will be prepared with brain sections of 10
microns thickness. The slides will be stained with antibody against
LDLR and evaluated to determine whether the signals for LDLR and
the ApoE peptide are co-localized.
Example 4--Location of K.sub.16ApoE (SEQ ID NO: 22) Following
Delivery Across the BBB
[0101] The experiments will determine the location of protein
delivery by the carrier peptide (K.sub.16ApoE SEQ ID NO: 22))
within the brain. K.sub.16ApoE (e.g., SEQ ID NO: 22)+ Alexa-IgG
(green fluorescence) conjugate will be prepared by mixing solutions
of each at the desired concentrations and incubating the mixture at
room temp for 30 minutes. The complex will be injected into mice
and brain specimens collected after 1 hour. Slides will be prepared
as above, and immunostained for GFAP, calbindin and neuregulin. If
co-localization of IgG and GFAP is seen, such a result may indicate
that the delivered IgG reached the astrocytes. Co-localization of
IgG and calbindin or neuregulin, however, may indicate that the
delivered IgG reached the neurons.
Example 5--Compromised Integrity of the BBB by K.sub.16ApoE (SEQ ID
NO: 22)
[0102] These experiments will evaluate whether the K.sub.16ApoE
(e.g., SEQ ID NO:22), alone or following formation of a complex,
compromises the integrity of the BBB. A complex with K.sub.16ApoE
(SEQ ID NO: 22)+AlexaRedIgG will be prepared and injected into
mice. After 1 hour uncomplexed AlexaGreenlgG will be injected.
Brain specimens will be collected 1 hour after the second
injection, and slides will be prepared using 10 micron sections.
The sections will be visualized using confocal microscopy. In other
mice, the reverse the experimental approach will be implemented
using AlexaGreenlgG complexed with K.sub.16ApoE (SEQ ID NO: 22) and
uncomplexed AlexaRedIgG. If the peptide does not compromise the
BBB, then only red fluorescence will be seen in cells in the brain.
However, if the peptide does compromise the BBB, then both red and
green fluorescence will be seen, and vice versa.
Example 6--Evaluation of microSPECT
[0103] A microSPECT machine can image and quantify radioactivity in
various tissues in live animals under anesthesia. If K.sub.16ApoE
(SEQ ID NO: 22) indeed carries a protein (radioactive) across the
BBB, then there should be more radioactivity in the brain of a mice
injected with such a peptide-protein complex than in the brain of a
mice injected with the radioactive protein alone.
[0104] IgG 4.1 (an antibody against the amyloid precursor protein
(APP)) was radioiodinated. IgG4.1 alone or previously complexed
with K.sub.16ApoE (SEQ ID NO:22) was injected in a number of mice.
The mice were anesthesized and the brain was imaged with a
microSPECT machine at 1 hour intervals. Perfusion was done for some
mice after six hours of quantitative imaging followed by imaging
after 30 minutes.
[0105] The radioactivity measured at each time point for each mice
was plotted against time (FIG. 2). Seven animals were used in
total, they are numbered M3-M9. M3 and M4 mice were not perfused.
Two mice (M5 and M7) receiving IgG 4.1 were perfused after 6 hours
of imaging, and three mice (M6, M8 and M9) receiving the IgG
complexed with the delivery peptide were perfused after 6 hours of
imaging followed by imaging at 6.5 hours.
[0106] It is clear from the data presented in FIG. 2 that
.about.2-fold more radioactivity was registered in the brains of
mice delivered with the IgG complexed with the peptide than the IgG
alone. This difference increased to nearly 5-fold when the animals
were perfused.
[0107] Radioactivity in the brains of mice receiving IgG alone
indicated IgG molecules were retained in the capillaries. Increased
accumulation of radioactivity in the brains of mice receiving the
IgG complexed with the delivery peptide indicated IgGs were present
in the capillaries as well as having crossed the BBB and retained
in the brain. If the IgG crosses the BBB and is retained in brain
cells, then perfusion of the brains should eliminate IgGs in the
capillaries but IgGs that have crossed the BBB should still be
retained, which is essentially seen for mice M6, M8 and M9,
providing strong indication that the peptide helps carry the
protein (IgG) through the BBB into the brain.
Example 7--Delivery of a Protein Across the BBB
[0108] To evaluate the potential of K16ApoE (SEQ ID NO: 22) for
delivering a protein across the BBB, the enzyme
.beta.-galactosidase was injected in mice with or without prior
mixing with K16ApoE (SEQ ID NO: 22) (at a protein to peptide molar
ratio of 1:70). The experiment was repeated more than a dozen
times. In this series of experiments, intense .beta.-galactosidase
activity was observed in mice brain when the enzyme-peptide mix was
injected and brain slices were prepared for enzyme activity
staining 6 hours after injection, whereas no activity was seen when
the enzyme was injected alone (FIG. 3A). High-magnification scans
of the images of .beta.-galactosidase-stained sections in the brain
showed that the enzyme was delivered in virtually every area of the
brain, and stained both astrocytes and neurons, however, pyramidal
cells in the hippocampus showed much weaker staining for
.beta.-galactosidase activity compared to cells in other areas of
the brain. The weak .beta.-galactosidase activity staining in the
pyramidal cells does not appear to be due to low expression of LDLR
in mouse hippocampus since cells in this region display strong
immunohistochemical staining for the receptor. It is speculated
that either X-gal or 5-bromo-4-chloroindole or both somehow leach
out of this region faster than other regions of the brain resulting
to a faint signal for .beta.-galactosidase activity.
[0109] To assess if the delivery of .beta.-galactosidase in the
brain via K16ApoE (SEQ ID NO: 22) is LDLR-mediated,
.beta.-galactosidase staining in liver, brain, kidney, heart and
lung after injection of the enzyme with and without mixing with
K16ApoE (SEQ ID NO: 22) was also evaluated. The most intense
staining was observed in liver and brain, followed by staining in
lung, heart and kidney (FIG. 3B-G). This pattern of uptake of
beta-galactosidase by K16ApoE (SEQ ID NO: 22) in various organs
approximately follows the pattern of reported LDLR expression
pattern suggesting that delivery of .beta.-galactosidase through
K16ApoE (SEQ ID NO: 22) is LDLR-mediated.
Example 8--Delivery of IgG and IgM Using K16ApoE
[0110] Since many potentially therapeutic proteins against
brain-associated disorders are immunoglobulins, delivery of IgG and
IgM through K16ApoE (SEQ ID NO: 22) in mouse brain was evaluated by
micro-single photon emission computed tomography (microSPECT)
imaging. For this, radioiodinated human IgG (Sigma, product # I
4506) and human IgM (Sigma, product # I 8260) were mixed with
K16ApoE (SEQ ID NO: 22) and injected intravenously. Anesthetized
animals were then subjected to imaging for 6 hours at 1 hour
interval. Cardiac perfusion was then performed, after which final
imaging was done at 30 minutes post-perfusion. Results from these
experiments provide a number of indications (FIG. 4): First, it
appears that peak delivery of both IgG and IgM into brain happens
around 2 hours post-injection of the peptide-protein mix, after
which uptake of the proteins in the brain remains relatively
unchanged up to 6 hours (maximum time point tested). Second,
cardiac perfusion appears to remove most of the radioactive protein
in the vasculature, concomitantly increasing the difference between
apparent brain-uptake of the protein with and without the carrier
peptide (.about.5-fold). Finally, the results suggest that about 1%
of the injected immunoglobulins are transported into the brain by
K16ApoE (SEQ ID NO: 22) under the experimental condition. It is
interesting to note that the extent of delivery of the radiolabeled
IgG and IgM into kidney, liver/spleen and heart remained virtually
unchanged irrespective of whether the proteins were delivered with
or without the carrier peptide. Cardiac perfusion also did not
change the accumulation of radioactivity in these organs, implying
that transport of proteins in these organs does not depend upon
crossing of a biological barrier.
Example 9--Efficacy of Delivered Therapeutic
[0111] For its activity, .beta.-galactosidase does not need to bind
with any molecular entity in the brain. However, for all
therapeutic purposes, the delivered molecule in the brain must be
able to recognize and bind with its cognate target molecule. To
test this premise, an antibody against amyloid beta peptide (4G8
from Cavance) was delivered via K16ApoE (SEQ ID NO: 22) in the
brains of mice which model for Alzheimer's disease. This antibody
is known to recognize amyloid beta plaques. The results indicate
that the antibody delivered in this manner labeled the amyloid
plaques in the brain of these mice as well as identifyed the
plaques with the antibody through standard immunohistochemistry
(FIG. 5). Similar results were also obtained with another antibody
(4.1 IgG, 32) known to label these plaques.
Example 10--Transportation of Protein without Damage to BBB
[0112] A transporter that efficiently carries a protein in the
brain should not do so by impairing the integrity of the BBB. To
evaluate if K16ApoE (SEQ ID NO: 22) impairs the integrity of the
BBB, the peptide was first injected intravenously, then injected
.beta.-galactosidase at different time intervals. The control mice
received the enzyme mixed with the peptide. Mice were perfused and
sacrificed 6 hours after .beta.-galactosidase injection, brain
slices were made and prepared for .beta.-galactosidase staining.
Results presented in FIG. 6 show increasingly weaker
.beta.-galactosidase activity in the brains of mice receiving
.beta.-galactosidase at 1, 5 and 10 minutes after injection of
K16ApoE (SEQ ID NO: 22) and no visible staining thereafter. These
results indicate that most of the injected K16ApoE (SEQ ID NO: 22)
becomes bound with proteins and cells in the circulation, and this
binding becomes virtually complete within 10 minutes after which no
free K16APoE (SEQ ID NO: 22) remains in circulation. Free K16ApoE
(SEQ ID NO: 22) that remains at early time points becomes bound
with beta-galactosidase and carries the enzyme in the brain. The
peptide by itself and/or being bound with blood proteins/cells did
not seem to affect the BBB as no .beta.-galactosidase enzyme
activity was seen in the brain from 10 min to 4 hours.
Example 11--Necessity of Covalent Linking of Hydrophillic Amino
Acid Chain and Carrier Peptide
[0113] The necessity of covalent linking of the K16 (SEQ ID NO: 4)
and ApoE (SEQ ID NO: 13) peptide moieties was evaluated for
non-covalent transport of a protein across the BBB. For this,
.beta.-galactosidase was mixed with either the ApoE peptide, the
peptide K16 (SEQ ID NO: 4), ApoE plus K16 (SEQ ID NO: 4) or with
K16ApoE (SEQ ID NO: 22), and injected in mice. Brain sections from
these mice show .beta.-galactosidase staining only in slides from
mice receiving .beta.-galactosidase mixed with K16ApoE (SEQ ID NO:
22), indicating that linking of the K16 (SEQ ID NO: 4) and the ApoE
peptide moieties is critical for transport of a protein in a
non-covalent manner (FIG. 7).
Example 12--Testing Mutant ApoE Peptides for their Potential as
Non-Covalent Transporters of Proteins Across the BBB
[0114] .beta.-galactosidase was mixed with equal amounts of various
peptide transporters and injected into mice. Slides were prepared
using 25 .mu.m sections of the mice brains one hour after injection
followed by development of enzyme staining (FIG. 8). The following
peptides were evaluated:
TABLE-US-00010 A: (SEQ ID NO: 126) KKKK KKKK KKKK KKKK LRLR LANH
LRKL RKRL LRDA; B: (SEQ ID NO: 127) KKKK KKKK KKKK KKKK LRLR LASH
LRKL RKRL LRDL; C: (SEQ ID NO: 128) KKKK KKKK KKKK KKKK LRVR LANH
LRKL RKRL LRDL.
As shown in FIG. 8, mutant A was worse than the wild-type ApoE
blood-brain barrier agent, while mutants B and C were able to
transport the .beta.-galactosidase at least as well as wild-type or
better.
Example 13--Time Course for .beta.-Galactosidase Delivery in Mouse
Brain with K16ApoE (SEQ ID NO: 22)
[0115] In each mouse, 1.38 nanomoles of .beta.-galactosidase was
mixed with 89 nanomoles of K16ApoE (SEQ ID NO: 22) and injected
intravenously. 25 .mu.m brain slices were prepared for staining for
.beta.-galactosidase activity at indicated time points (FIG. 9).
FIG. 8 provides the following time points:
A--Beta-galactosidase, no peptide, 6 h. B--Beta-galactosidase+
peptide, 1 h. C--Beta-galactosidase+ peptide, 2 h.
D--Beta-galactosidase+ peptide, 5 h. E--Beta-galactosidase+
peptide, 10 h.
[0116] A number of embodiments of the invention have been
described. Nevertheless, it will be understood that various
modifications may be made without departing from the spirit and
scope of the invention. Accordingly, other embodiments are within
the scope of the following claims.
Sequence CWU 1
1
14314PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 1Lys Lys Lys Lys128PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 2Lys
Lys Lys Lys Lys Lys Lys Lys1 5312PRTArtificial SequenceDescription
of Artificial Sequence Synthetic peptide 3Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys Lys1 5 10416PRTArtificial SequenceDescription
of Artificial Sequence Synthetic peptide 4Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1 5 10 1554PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 5Arg
Arg Arg Arg168PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 6Arg Arg Arg Arg Arg Arg Arg Arg1
5712PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 7Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg1
5 10816PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 8Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg
Arg Arg Arg Arg1 5 10 1594PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 9Lys Arg Lys
Arg1104PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 10Lys Lys Lys Arg11112PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 11Lys
Lys Lys Arg Arg Arg Lys Lys Lys Arg Arg Arg1 5 101216PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 12Lys
Lys Lys Lys Arg Arg Arg Arg Lys Lys Lys Lys Arg Arg Arg Arg1 5 10
151320PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 13Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Leu
Arg Lys Arg Leu1 5 10 15Leu Arg Asp Ala 201440PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
14Ser Ser Val Ile Asp Ala Leu Gln Tyr Lys Leu Glu Gly Thr Thr Arg1
5 10 15Leu Thr Arg Lys Arg Gly Leu Lys Leu Ala Thr Ala Leu Ser Leu
Ser 20 25 30Asn Lys Phe Val Glu Gly Ser His 35 401536PRTArtificial
SequenceDescription of Artificial Sequence Synthetic
polypeptideMOD_RES(36)..(36)Tyr or a Tyr derivative 15Tyr Pro Ala
Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu1 5 10 15Leu Ser
Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr 20 25 30Arg
Gln Arg Xaa 351634PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptideMOD_RES(34)..(34)Tyr or a Tyr
derivative 16Ala Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu
Glu Leu Ser1 5 10 15Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu
Val Thr Arg Gln 20 25 30Arg Xaa1736PRTArtificial
SequenceDescription of Artificial Sequence Synthetic
polypeptideMOD_RES(36)..(36)Tyr or a Tyr derivative 17Tyr Pro Ser
Asp Pro Asp Asn Pro Gly Glu Asp Ala Pro Ala Glu Asp1 5 10 15Leu Ala
Arg Tyr Tyr Ser Ala Leu Arg His Tyr Ile Asn Leu Ile Thr 20 25 30Arg
Gln Arg Xaa 351836PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptideMOD_RES(36)..(36)Tyr or a Tyr
derivative 18Ala Pro Leu Glu Pro Val Tyr Pro Gly Asp Asp Ala Thr
Pro Glu Gln1 5 10 15Met Ala Gln Tyr Ala Ala Glu Leu Arg Arg Tyr Ile
Asn Met Leu Thr 20 25 30Arg Pro Arg Xaa 351924PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 19Lys
Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Leu1 5 10
15Arg Lys Arg Leu Leu Arg Asp Ala 202028PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 20Lys
Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His1 5 10
15Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala 20
252132PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 21Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
Lys Leu Arg Val Arg1 5 10 15Leu Ala Ser His Leu Arg Lys Leu Arg Lys
Arg Leu Leu Arg Asp Ala 20 25 302236PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
22Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1
5 10 15Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Leu Arg Lys Arg
Leu 20 25 30Leu Arg Asp Ala 352340PRTArtificial SequenceDescription
of Artificial Sequence Synthetic polypeptide 23Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1 5 10 15Lys Lys Lys Lys
Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Leu 20 25 30Arg Lys Arg
Leu Leu Arg Asp Ala 35 402444PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 24Lys Lys Lys Lys Ser Ser
Val Ile Asp Ala Leu Gln Tyr Lys Leu Glu1 5 10 15Gly Thr Thr Arg Leu
Thr Arg Lys Arg Gly Leu Lys Leu Ala Thr Ala 20 25 30Leu Ser Leu Ser
Asn Lys Phe Val Glu Gly Ser His 35 402548PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
25Lys Lys Lys Lys Lys Lys Lys Lys Ser Ser Val Ile Asp Ala Leu Gln1
5 10 15Tyr Lys Leu Glu Gly Thr Thr Arg Leu Thr Arg Lys Arg Gly Leu
Lys 20 25 30Leu Ala Thr Ala Leu Ser Leu Ser Asn Lys Phe Val Glu Gly
Ser His 35 40 452652PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 26Lys Lys Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Ser Ser Val Ile1 5 10 15Asp Ala Leu Gln Tyr Lys Leu
Glu Gly Thr Thr Arg Leu Thr Arg Lys 20 25 30Arg Gly Leu Lys Leu Ala
Thr Ala Leu Ser Leu Ser Asn Lys Phe Val 35 40 45Glu Gly Ser His
502756PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 27Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys1 5 10 15Ser Ser Val Ile Asp Ala Leu Gln Tyr Lys
Leu Glu Gly Thr Thr Arg 20 25 30Leu Thr Arg Lys Arg Gly Leu Lys Leu
Ala Thr Ala Leu Ser Leu Ser 35 40 45Asn Lys Phe Val Glu Gly Ser His
50 552860PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 28Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys1 5 10 15Lys Lys Lys Lys Ser Ser Val Ile Asp Ala
Leu Gln Tyr Lys Leu Glu 20 25 30Gly Thr Thr Arg Leu Thr Arg Lys Arg
Gly Leu Lys Leu Ala Thr Ala 35 40 45Leu Ser Leu Ser Asn Lys Phe Val
Glu Gly Ser His 50 55 602920PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptideMOD_RES(3)..(3)Ala, Leu, Ser,
or ValMOD_RES(5)..(5)Leu or MetMOD_RES(6)..(6)Ala or
SerMOD_RES(7)..(7)Asn, Ser, or ThrMOD_RES(11)..(11)Lys or
AsnMOD_RES(12)..(12)Leu, Met, or ValMOD_RES(13)..(13)Arg or
ProMOD_RES(17)..(17)Leu or MetMOD_RES(20)..(20)Ala or Leu 29Leu Arg
Xaa Arg Xaa Xaa Xaa His Leu Arg Xaa Xaa Xaa Lys Arg Leu1 5 10 15Xaa
Arg Asp Xaa 203020PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 30Leu Arg Ser Arg Leu Ala Ser His Leu
Arg Lys Leu Arg Lys Arg Leu1 5 10 15Leu Arg Asp Ala
203120PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 31Leu Arg Val Arg Met Ala Ser His Leu Arg Lys Leu
Arg Lys Arg Leu1 5 10 15Leu Arg Asp Ala 203220PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 32Leu
Arg Val Arg Leu Ala Thr His Leu Arg Lys Leu Arg Lys Arg Leu1 5 10
15Leu Arg Asp Ala 203320PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 33Leu Arg Val Arg Leu Ala Ser
His Leu Arg Lys Leu Pro Lys Arg Leu1 5 10 15Leu Arg Asp Ala
203420PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 34Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Leu
Arg Lys Arg Leu1 5 10 15Met Arg Asp Ala 203520PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 35Leu
Arg Val Arg Leu Ala Ser His Leu Arg Asn Leu Arg Lys Arg Leu1 5 10
15Leu Arg Asp Ala 203620PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 36Leu Arg Val Arg Leu Ala Ser
His Leu Arg Lys Val Arg Lys Arg Leu1 5 10 15Leu Arg Asp Ala
203720PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 37Leu Arg Val Arg Met Ser Ser His Leu Arg Lys Leu
Arg Lys Arg Leu1 5 10 15Leu Arg Asp Ala 203820PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 38Leu
Arg Val Arg Leu Ala Ser His Leu Arg Asn Val Arg Lys Arg Leu1 5 10
15Leu Arg Asp Ala 203920PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 39Leu Arg Val Arg Leu Ala Ser
His Leu Arg Asn Met Arg Lys Arg Leu1 5 10 15Leu Arg Asp Ala
204020PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 40Leu Arg Ala Arg Met Ala Ser His Leu Arg Lys Leu
Arg Lys Arg Leu1 5 10 15Leu Arg Asp Ala 204120PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 41Leu
Arg Val Arg Leu Ser Ser His Leu Arg Lys Leu Arg Lys Arg Leu1 5 10
15Met Arg Asp Ala 204220PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 42Leu Arg Ser Arg Leu Ala Ser
His Leu Arg Lys Leu Arg Lys Arg Leu1 5 10 15Met Arg Asp Ala
204320PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 43Leu Arg Val Arg Leu Ser Ser His Leu Pro Lys Leu
Arg Lys Arg Leu1 5 10 15Leu Arg Asp Ala 204420PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 44Leu
Arg Val Arg Leu Ala Ser His Leu Arg Lys Met Arg Lys Arg Leu1 5 10
15Met Arg Asp Ala 204520PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 45Leu Arg Val Arg Leu Ala Ser
His Leu Arg Asn Leu Pro Lys Arg Leu1 5 10 15Leu Arg Asp Ala
204624PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 46Lys Lys Lys Lys Leu Arg Ser Arg Leu Ala Ser His
Leu Arg Lys Leu1 5 10 15Arg Lys Arg Leu Leu Arg Asp Ala
204728PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 47Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Ser Arg
Leu Ala Ser His1 5 10 15Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp
Ala 20 254832PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 48Lys Lys Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Leu Arg Ser Arg1 5 10 15Leu Ala Ser His Leu Arg Lys
Leu Arg Lys Arg Leu Leu Arg Asp Ala 20 25 304936PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
49Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1
5 10 15Leu Arg Ser Arg Leu Ala Ser His Leu Arg Lys Leu Arg Lys Arg
Leu 20 25 30Leu Arg Asp Ala 355040PRTArtificial SequenceDescription
of Artificial Sequence Synthetic polypeptide 50Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1 5 10 15Lys Lys Lys Lys
Leu Arg Ser Arg Leu Ala Ser His Leu Arg Lys Leu 20 25 30Arg Lys Arg
Leu Leu Arg Asp Ala 35 405124PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 51Lys Lys Lys Lys Leu Arg Val
Arg Met Ala Ser His Leu Arg Lys Leu1 5 10 15Arg Lys Arg Leu Leu Arg
Asp Ala 205228PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 52Lys Lys Lys Lys Lys Lys Lys Lys Leu
Arg Val Arg Met Ala Ser His1 5 10 15Leu Arg Lys Leu Arg Lys Arg Leu
Leu Arg Asp Ala 20 255332PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 53Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys Lys Leu Arg Val Arg1 5 10 15Met Ala Ser His Leu
Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala 20 25
305436PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 54Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys1 5 10 15Leu Arg Val Arg Met Ala Ser His Leu Arg
Lys Leu Arg Lys Arg Leu 20 25 30Leu Arg Asp Ala 355540PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
55Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1
5 10 15Lys Lys Lys Lys Leu Arg Val Arg Met Ala Ser His Leu Arg Lys
Leu 20 25 30Arg Lys Arg Leu Leu Arg Asp Ala 35 405624PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 56Lys
Lys Lys Lys Leu Arg Val Arg Leu Ala Thr His Leu Arg Lys Leu1 5 10
15Arg Lys Arg Leu Leu Arg Asp Ala 205728PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 57Lys
Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Thr His1 5 10
15Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala 20
255832PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 58Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
Lys Leu Arg Val Arg1 5 10 15Leu Ala Thr His Leu Arg Lys Leu Arg Lys
Arg Leu Leu Arg Asp Ala 20 25 305936PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
59Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1
5 10 15Leu Arg Val Arg Leu Ala Thr His Leu Arg Lys Leu Arg Lys Arg
Leu 20 25 30Leu Arg Asp Ala 356040PRTArtificial SequenceDescription
of Artificial Sequence Synthetic polypeptide 60Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1 5 10 15Lys Lys Lys Lys
Leu Arg Val Arg Leu Ala Thr His Leu Arg Lys Leu 20 25 30Arg Lys Arg
Leu Leu Arg Asp Ala 35 406124PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 61Lys Lys Lys Lys Leu Arg Val
Arg Leu Ala Ser His Leu Arg Lys Leu1 5 10 15Pro Lys Arg Leu Leu Arg
Asp Ala 206228PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 62Lys Lys Lys Lys Lys Lys Lys Lys Leu
Arg Val Arg Leu Ala Ser His1 5 10 15Leu Arg Lys Leu Pro Lys Arg Leu
Leu Arg Asp Ala 20 256332PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 63Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys Lys Leu Arg Val Arg1 5 10 15Leu Ala Ser His Leu
Arg Lys Leu Pro Lys Arg Leu Leu Arg Asp Ala 20 25
306436PRTArtificial SequenceDescription
of Artificial Sequence Synthetic polypeptide 64Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1 5 10 15Leu Arg Val Arg
Leu Ala Ser His Leu Arg Lys Leu Pro Lys Arg Leu 20 25 30Leu Arg Asp
Ala 356540PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 65Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys1 5 10 15Lys Lys Lys Lys Leu Arg Val Arg Leu Ala
Ser His Leu Arg Lys Leu 20 25 30Pro Lys Arg Leu Leu Arg Asp Ala 35
406624PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 66Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His
Leu Arg Lys Leu1 5 10 15Arg Lys Arg Leu Met Arg Asp Ala
206728PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 67Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg
Leu Ala Ser His1 5 10 15Leu Arg Lys Leu Arg Lys Arg Leu Met Arg Asp
Ala 20 256832PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 68Lys Lys Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Leu Arg Val Arg1 5 10 15Leu Ala Ser His Leu Arg Lys
Leu Arg Lys Arg Leu Met Arg Asp Ala 20 25 306936PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
69Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1
5 10 15Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Leu Arg Lys Arg
Leu 20 25 30Met Arg Asp Ala 357040PRTArtificial SequenceDescription
of Artificial Sequence Synthetic polypeptide 70Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1 5 10 15Lys Lys Lys Lys
Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Leu 20 25 30Arg Lys Arg
Leu Met Arg Asp Ala 35 407124PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 71Lys Lys Lys Lys Leu Arg Val
Arg Leu Ala Ser His Leu Arg Asn Leu1 5 10 15Arg Lys Arg Leu Leu Arg
Asp Ala 207228PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 72Lys Lys Lys Lys Lys Lys Lys Lys Leu
Arg Val Arg Leu Ala Ser His1 5 10 15Leu Arg Asn Leu Arg Lys Arg Leu
Leu Arg Asp Ala 20 257332PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 73Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys Lys Leu Arg Val Arg1 5 10 15Leu Ala Ser His Leu
Arg Asn Leu Arg Lys Arg Leu Leu Arg Asp Ala 20 25
307436PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 74Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys1 5 10 15Leu Arg Val Arg Leu Ala Ser His Leu Arg
Asn Leu Arg Lys Arg Leu 20 25 30Leu Arg Asp Ala 357540PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
75Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1
5 10 15Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His Leu Arg Asn
Leu 20 25 30Arg Lys Arg Leu Leu Arg Asp Ala 35 407624PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 76Lys
Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Val1 5 10
15Arg Lys Arg Leu Leu Arg Asp Ala 207728PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 77Lys
Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His1 5 10
15Leu Arg Lys Val Arg Lys Arg Leu Leu Arg Asp Ala 20
257832PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 78Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
Lys Leu Arg Val Arg1 5 10 15Leu Ala Ser His Leu Arg Lys Val Arg Lys
Arg Leu Leu Arg Asp Ala 20 25 307936PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
79Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1
5 10 15Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Val Arg Lys Arg
Leu 20 25 30Leu Arg Asp Ala 358040PRTArtificial SequenceDescription
of Artificial Sequence Synthetic polypeptide 80Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1 5 10 15Lys Lys Lys Lys
Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Val 20 25 30Arg Lys Arg
Leu Leu Arg Asp Ala 35 408124PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 81Lys Lys Lys Lys Leu Arg Val
Arg Met Ser Ser His Leu Arg Lys Leu1 5 10 15Arg Lys Arg Leu Leu Arg
Asp Ala 208228PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 82Lys Lys Lys Lys Lys Lys Lys Lys Leu
Arg Val Arg Met Ser Ser His1 5 10 15Leu Arg Lys Leu Arg Lys Arg Leu
Leu Arg Asp Ala 20 258332PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 83Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys Lys Leu Arg Val Arg1 5 10 15Met Ser Ser His Leu
Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala 20 25
308436PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 84Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys1 5 10 15Leu Arg Val Arg Met Ser Ser His Leu Arg
Lys Leu Arg Lys Arg Leu 20 25 30Leu Arg Asp Ala 358540PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
85Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1
5 10 15Lys Lys Lys Lys Leu Arg Val Arg Met Ser Ser His Leu Arg Lys
Leu 20 25 30Arg Lys Arg Leu Leu Arg Asp Ala 35 408624PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 86Lys
Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His Leu Arg Asn Val1 5 10
15Arg Lys Arg Leu Leu Arg Asp Ala 208728PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 87Lys
Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His1 5 10
15Leu Arg Asn Val Arg Lys Arg Leu Leu Arg Asp Ala 20
258832PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 88Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
Lys Leu Arg Val Arg1 5 10 15Leu Ala Ser His Leu Arg Asn Val Arg Lys
Arg Leu Leu Arg Asp Ala 20 25 308936PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
89Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1
5 10 15Leu Arg Val Arg Leu Ala Ser His Leu Arg Asn Val Arg Lys Arg
Leu 20 25 30Leu Arg Asp Ala 359040PRTArtificial SequenceDescription
of Artificial Sequence Synthetic polypeptide 90Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1 5 10 15Lys Lys Lys Lys
Leu Arg Val Arg Leu Ala Ser His Leu Arg Asn Val 20 25 30Arg Lys Arg
Leu Leu Arg Asp Ala 35 409124PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 91Lys Lys Lys Lys Leu Arg Val
Arg Leu Ala Ser His Leu Arg Asn Met1 5 10 15Arg Lys Arg Leu Leu Arg
Asp Ala 209228PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 92Lys Lys Lys Lys Lys Lys Lys Lys Leu
Arg Val Arg Leu Ala Ser His1 5 10 15Leu Arg Asn Met Arg Lys Arg Leu
Leu Arg Asp Ala 20 259332PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 93Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys Lys Leu Arg Val Arg1 5 10 15Leu Ala Ser His Leu
Arg Asn Met Arg Lys Arg Leu Leu Arg Asp Ala 20 25
309436PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 94Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys1 5 10 15Leu Arg Val Arg Leu Ala Ser His Leu Arg
Asn Met Arg Lys Arg Leu 20 25 30Leu Arg Asp Ala 359540PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
95Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1
5 10 15Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His Leu Arg Asn
Met 20 25 30Arg Lys Arg Leu Leu Arg Asp Ala 35 409624PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 96Lys
Lys Lys Lys Leu Arg Ala Arg Met Ala Ser His Leu Arg Lys Leu1 5 10
15Arg Lys Arg Leu Leu Arg Asp Ala 209728PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 97Lys
Lys Lys Lys Lys Lys Lys Lys Leu Arg Ala Arg Met Ala Ser His1 5 10
15Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala 20
259832PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 98Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
Lys Leu Arg Ala Arg1 5 10 15Met Ala Ser His Leu Arg Lys Leu Arg Lys
Arg Leu Leu Arg Asp Ala 20 25 309936PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
99Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1
5 10 15Leu Arg Ala Arg Met Ala Ser His Leu Arg Lys Leu Arg Lys Arg
Leu 20 25 30Leu Arg Asp Ala 3510040PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
100Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1
5 10 15Lys Lys Lys Lys Leu Arg Ala Arg Met Ala Ser His Leu Arg Lys
Leu 20 25 30Arg Lys Arg Leu Leu Arg Asp Ala 35 4010124PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 101Lys
Lys Lys Lys Leu Arg Val Arg Leu Ser Ser His Leu Arg Lys Leu1 5 10
15Arg Lys Arg Leu Met Arg Asp Ala 2010228PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 102Lys
Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg Leu Ser Ser His1 5 10
15Leu Arg Lys Leu Arg Lys Arg Leu Met Arg Asp Ala 20
2510332PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 103Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
Lys Lys Leu Arg Val Arg1 5 10 15Leu Ser Ser His Leu Arg Lys Leu Arg
Lys Arg Leu Met Arg Asp Ala 20 25 3010436PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
104Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1
5 10 15Leu Arg Val Arg Leu Ser Ser His Leu Arg Lys Leu Arg Lys Arg
Leu 20 25 30Met Arg Asp Ala 3510540PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
105Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1
5 10 15Lys Lys Lys Lys Leu Arg Val Arg Leu Ser Ser His Leu Arg Lys
Leu 20 25 30Arg Lys Arg Leu Met Arg Asp Ala 35 4010624PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 106Lys
Lys Lys Lys Leu Arg Ser Arg Leu Ala Ser His Leu Arg Lys Leu1 5 10
15Arg Lys Arg Leu Met Arg Asp Ala 2010728PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 107Lys
Lys Lys Lys Lys Lys Lys Lys Leu Arg Ser Arg Leu Ala Ser His1 5 10
15Leu Arg Lys Leu Arg Lys Arg Leu Met Arg Asp Ala 20
2510832PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 108Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
Lys Lys Leu Arg Ser Arg1 5 10 15Leu Ala Ser His Leu Arg Lys Leu Arg
Lys Arg Leu Met Arg Asp Ala 20 25 3010936PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
109Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1
5 10 15Leu Arg Ser Arg Leu Ala Ser His Leu Arg Lys Leu Arg Lys Arg
Leu 20 25 30Met Arg Asp Ala 3511040PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
110Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1
5 10 15Lys Lys Lys Lys Leu Arg Ser Arg Leu Ala Ser His Leu Arg Lys
Leu 20 25 30Arg Lys Arg Leu Met Arg Asp Ala 35 4011124PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 111Lys
Lys Lys Lys Leu Arg Val Arg Leu Ser Ser His Leu Pro Lys Leu1 5 10
15Arg Lys Arg Leu Leu Arg Asp Ala 2011228PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 112Lys
Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg Leu Ser Ser His1 5 10
15Leu Pro Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala 20
2511332PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 113Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
Lys Lys Leu Arg Val Arg1 5 10 15Leu Ser Ser His Leu Pro Lys Leu Arg
Lys Arg Leu Leu Arg Asp Ala 20 25 3011436PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
114Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1
5 10 15Leu Arg Val Arg Leu Ser Ser His Leu Pro Lys Leu Arg Lys Arg
Leu 20 25 30Leu Arg Asp Ala 3511540PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
115Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1
5 10 15Lys Lys Lys Lys Leu Arg Val Arg Leu Ser Ser His Leu Pro Lys
Leu 20 25 30Arg Lys Arg Leu Leu Arg Asp Ala 35 4011624PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 116Lys
Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Met1 5 10
15Arg Lys Arg Leu Met Arg Asp Ala 2011728PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 117Lys
Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His1 5 10
15Leu Arg Lys Met Arg Lys Arg Leu Met Arg Asp Ala 20
2511832PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 118Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
Lys Lys Leu Arg Val Arg1 5 10 15Leu Ala Ser His Leu Arg Lys Met Arg
Lys Arg Leu Met Arg Asp Ala 20 25 3011936PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
119Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1
5 10 15Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Met Arg Lys Arg
Leu 20 25
30Met Arg Asp Ala 3512040PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 120Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1 5 10 15Lys Lys Lys Lys
Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Met 20 25 30Arg Lys Arg
Leu Met Arg Asp Ala 35 4012124PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 121Lys Lys Lys Lys Leu Arg
Val Arg Leu Ala Ser His Leu Arg Asn Leu1 5 10 15Pro Lys Arg Leu Leu
Arg Asp Ala 2012228PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 122Lys Lys Lys Lys Lys Lys Lys Lys Leu
Arg Val Arg Leu Ala Ser His1 5 10 15Leu Arg Asn Leu Pro Lys Arg Leu
Leu Arg Asp Ala 20 2512332PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 123Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg1 5 10 15Leu Ala Ser His
Leu Arg Asn Leu Pro Lys Arg Leu Leu Arg Asp Ala 20 25
3012436PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 124Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys Lys1 5 10 15Leu Arg Val Arg Leu Ala Ser His Leu
Arg Asn Leu Pro Lys Arg Leu 20 25 30Leu Arg Asp Ala
3512540PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 125Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys Lys1 5 10 15Lys Lys Lys Lys Leu Arg Val Arg Leu
Ala Ser His Leu Arg Asn Leu 20 25 30Pro Lys Arg Leu Leu Arg Asp Ala
35 4012636PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 126Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys Lys1 5 10 15Leu Arg Leu Arg Leu Ala Asn His Leu
Arg Lys Leu Arg Lys Arg Leu 20 25 30Leu Arg Asp Ala
3512736PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 127Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys Lys1 5 10 15Leu Arg Leu Arg Leu Ala Ser His Leu
Arg Lys Leu Arg Lys Arg Leu 20 25 30Leu Arg Asp Leu
3512836PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 128Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys Lys1 5 10 15Leu Arg Val Arg Leu Ala Asn His Leu
Arg Lys Leu Arg Lys Arg Leu 20 25 30Leu Arg Asp Leu
3512920PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 129Leu Arg Leu Arg Leu Ala Ser His Leu Arg Lys
Leu Arg Lys Arg Leu1 5 10 15Leu Arg Asp Leu 2013020PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 130Leu
Arg Val Arg Leu Ala Asn His Leu Arg Lys Leu Arg Lys Arg Leu1 5 10
15Leu Arg Asp Leu 2013124PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 131Lys Lys Lys Lys Leu Arg
Leu Arg Leu Ala Ser His Leu Arg Lys Leu1 5 10 15Arg Lys Arg Leu Leu
Arg Asp Leu 2013228PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 132Lys Lys Lys Lys Lys Lys Lys Lys Leu
Arg Leu Arg Leu Ala Ser His1 5 10 15Leu Arg Lys Leu Arg Lys Arg Leu
Leu Arg Asp Leu 20 2513332PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 133Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys Lys Lys Leu Arg Leu Arg1 5 10 15Leu Ala Ser His
Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Leu 20 25
3013436PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 134Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys Lys1 5 10 15Leu Arg Leu Arg Leu Ala Ser His Leu
Arg Lys Leu Arg Lys Arg Leu 20 25 30Leu Arg Asp Leu
3513540PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 135Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Lys Lys1 5 10 15Lys Lys Lys Lys Leu Arg Leu Arg Leu
Ala Ser His Leu Arg Lys Leu 20 25 30Arg Lys Arg Leu Leu Arg Asp Leu
35 4013624PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 136Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Asn
His Leu Arg Lys Leu1 5 10 15Arg Lys Arg Leu Leu Arg Asp Leu
2013728PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 137Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val
Arg Leu Ala Asn His1 5 10 15Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg
Asp Leu 20 2513832PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 138Lys Lys Lys Lys Lys Lys Lys Lys
Lys Lys Lys Lys Leu Arg Val Arg1 5 10 15Leu Ala Asn His Leu Arg Lys
Leu Arg Lys Arg Leu Leu Arg Asp Leu 20 25 3013936PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
139Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1
5 10 15Leu Arg Val Arg Leu Ala Asn His Leu Arg Lys Leu Arg Lys Arg
Leu 20 25 30Leu Arg Asp Leu 3514040PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
140Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1
5 10 15Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Asn His Leu Arg Lys
Leu 20 25 30Arg Lys Arg Leu Leu Arg Asp Leu 35 4014120PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 141Leu
Arg Lys Leu Arg Lys Arg Leu Leu Arg Leu Arg Lys Leu Arg Lys1 5 10
15Arg Leu Leu Arg 2014240PRTArtificial SequenceDescription of
Artificial Sequence Synthetic
polypeptideMOD_RES(1)..(20)Hydrophilic amino acid and this region
may encompass 4 to 20 residuesMOD_RES(23)..(23)Ala, Leu, Ser, or
ValMOD_RES(25)..(25)Leu or MetMOD_RES(26)..(26)Ala or
SerMOD_RES(27)..(27)Asn, Ser, or ThrMOD_RES(31)..(31)Lys or
AsnMOD_RES(32)..(32)Leu, Met, or ValMOD_RES(33)..(33)Arg or
ProMOD_RES(37)..(37)Leu or MetMOD_RES(40)..(40)Ala or Leusee
specification as filed for detailed description of substitutions
and preferred embodiments 142Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5 10 15Xaa Xaa Xaa Xaa Leu Arg Xaa Arg
Xaa Xaa Xaa His Leu Arg Xaa Xaa 20 25 30Xaa Lys Arg Leu Xaa Arg Asp
Xaa 35 4014370PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptideMOD_RES(1)..(50)Hydrophilic amino
acid and this region may encompass 4 to 50
residuesMOD_RES(53)..(53)Ala, Leu, Ser, or ValMOD_RES(55)..(55)Leu
or MetMOD_RES(56)..(56)Ala or SerMOD_RES(57)..(57)Asn, Ser, or
ThrMOD_RES(61)..(61)Lys or AsnMOD_RES(62)..(62)Leu, Met, or
ValMOD_RES(63)..(63)Arg or ProMOD_RES(67)..(67)Leu or
MetMOD_RES(70)..(70)Ala or Leusee specification as filed for
detailed description of substitutions and preferred embodiments
143Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5 10 15Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa 20 25 30Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa 35 40 45Xaa Xaa Leu Arg Xaa Arg Xaa Xaa Xaa His Leu Arg Xaa
Xaa Xaa Lys 50 55 60Arg Leu Xaa Arg Asp Xaa65 70
* * * * *